

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <a href="mailto:info.bmjopen@bmj.com">info.bmjopen@bmj.com</a>

# **BMJ Open**

# Efficacy of dexmedetomidine in children during cleft lip and palate repair: a systematic review and meta-analysis

Journal:	
	BMJ Open
Manuscript ID	bmjopen-2020-046798
Article Type:	Original research
Date Submitted by the Author:	1 119-11077- 711 711
Complete List of Authors:	Liu, Dengfeng; Wenzhou Medical University, Department of Oral Maxillofacial Surgery Pan, Li; Wenzhou Medical University, Department of Oral Maxillofacial Surgery Gao, Yin; Wenzhou Medical University, Department of Oral Maxillofacial Surgery Liu, Jiefan; Wenzhou Medical University, Department of Oral Maxillofacial Surgery Li, Feng; Wenzhou Medical University, Department of Oral Maxillofacial Surgery Li, Xiangwei; Air Force Health Care Center For Special Service Hangzhou, Department of Rehabilitation Quan, Jiale; Wenzhou Medical University, Department of Anesthesiology and Perioperative Medicine HUANG, CONGCONG; Wenzhou Medical University Second Affiliated Hospital, Lian, Chunwei; Wenzhou Medical University
Keywords:	ORAL & MAXILLOFACIAL SURGERY, Paediatric anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Efficacy of dexmedetomidine in children during cleft lip and palate repair: a system review and meta-analysis

Dengfeng Liu<sup>1</sup>, Li Pan<sup>1</sup>, Yin Gao<sup>1</sup>, Jiefan Liu<sup>1</sup>, Feng Li<sup>1</sup>, Xiangwei Li<sup>3</sup>, Jiale Quan<sup>2</sup>,

Congcong Huang<sup>2\*</sup>, Chunwei Lian<sup>2\*\*</sup>

- 1.Department of Oral Maxillofacial Surgery, School and Hospital of Stomatology, Wenzhou Medical Univer \$\vec{\frac{3}}{2}\$ty, Wenzhou, Zhejiang, P.R. China.
- 2. Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical

University, Wenzhou, Zhejiang, P.R. China.

3. Department of Rehabilitation, Air Force Health Care Center For Special Service Hangzhou, Hangzhou, Zhejiang, P.R. China.

\*The Co-corresponding author: Dr. Congcong Huang

Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou

Medical University, 109 West Xueyuan Road, Wenzhou 325027, China.

E-mail: congconghuang2009@163.com

Tel: +86-13676757360

\*\*The Co-corresponding author: Dr. Chunwei Lian

Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou

Medical University, 109 West Xueyuan Road, Wenzhou 325027, China.

E-mail: lianchunwei0203@163.com

Tel: +86-13868702680

/bmjopen-2020-046798 on 16 Augus

#### **ABSTRACT**

Objective Dexmedetomidine was increasingly used in many areas and pediatric anesthesia setting for various indications. However, the efficacy of this intervention on pediatric patients in cleft lip and palate (CLP) repair was still unknown. We aimed to sestematically assess the efficacy and safety of dexmedetomidine as an anesthesia adjuvant during CLP repair in children.

Design Systematic review and meta-analysis.

Data sources PubMed, Embase, Cochrane library, CNKI, VIP, and Wanfang (up to Oct 2020). Studies in languages other than English and Chinese

were excluded.

Eligibility criteria for selecting studies Randomized controlled trials evaluating the impact of dexmedetomidine on emergence agitation (EA), the need for postoperative rescue analgesics, postoperative nausea and vomiting (PONV), and other adverse events in pediatric patients during CLP repair.

**Data extraction and synthesis** Data were screened, extracted and assessed by two independent authors. Our comes reported as a risk ratio (RR) with 95% confidence interval (CI). Random effects model was used when heterogeneity was detected, otherwise fixed effects model was chosen. Results Thirteen studies included 1040 children met the inclusion criteria. The incidence of EA was significantly decreased in the dexmedetomidine group (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I<sup>2</sup>=56%) as compared to the contro group. Pediatric patients receiving dexmedetomidine had lower postoperative analgesic requirements (RR, 0.27; 95% CI, 0.10 to 0.73; P=0x01; I<sup>2</sup>=84%) and less incidence of respiratory adverse events (RR, 0.49; 95% CI, 0.31 to 0.78; P=0.002; I<sup>2</sup>=0%). There were no significant deferences in the risk of PONV and

 cardiovascular adverse events.

Conclusions There was a lack of high-quality study in this field. Perioperative administration of dexmedetomidine reduced the need for postoperative rescue analgesics and the incidence of EA in children without side effects undergoing CLP repair. However, further verification with larger samples and more high quality RCTs would be needed.

Keywords children, dexmedetomidine, cleft lip and palate repair, pain, agitation

#### **ARTICLE SUMMARY**

# Strengths and limitations of this study

This is a comprehensive systematic review which identified the benefits of dexmedetomidine in children during CLP repair.

Different evaluation methods were used for the outcomes, even partial of which missed data on the definition detail, that would influence reliability

in future recommended guide for dexmedetomidine interventions.

Unfortunately, low quality of the included studies impedes us to draw firm conclusions.

Word account: 2632

/bmjopen-2020-046798 on 16 Aug

# **INTRODUCTION**

Cleft lip and palate (CLP) were widespread congenital disfigurement requiring surgical correction early in  $\bar{\xi}$  fe. Early surgery was important to alleviate feeding difficulty, reduce airway complications and improve phonation problem. 2 However, cleft palate repair needed to dissect the soft and hard palates and would result in significant postoperative oropharyngeal pain and bleeding. High-dose pioids with sevoflurane anesthesia were commonly used to block the autonomic response.<sup>3</sup> Due to above factors, many pediatric patients suffered from a high risk of respiratory depression, postoperative emergence agitation (EA), postoperative nausea and vomiting (PONV), a prolonge hospital stay and increased hospital costs.4-6

Dexmedetomidine was a potent α2 adrenoreceptor agonist with sedative, anxiolytic, sympatholytic and agalgesic properties. It also ensured a stable hemodynamic state and no significant respiratory depression. Study had demonstrated that it is proyed helpful as a valuable adjunct in many diverse areas and increasingly used in pediatric anesthesia setting. A meta-analysis recently showed hat perioperative administration of dexmedetomidine can provide pain and agitation relief without side effects in children undergoing adenoton adenoton. Another meta-analysis 10 found that intranasal dexmedetomidine provided more satisfactory sedation at parent separation and reduced the need for postoperative rescue analgesics in pediatric patients. However, evidence in the existing literature was insufficient to fully support the effectively and safely use of dexmedetomidine in CLP repair in children.

Therefore, our study was aimed to identify the effects of administration with dexmedetomidine in children during CLP repair. We performed otected by copyright a meta-analysis of randomized-controlled trials comparing dexmedetomidine with controls.

/bmjopen-2020-046798 on 16 Aug

#### **METHODS**

We evaluated the efficacy and safety of dexmedetomidine administration following CLP repair in children. Systematic approach based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Cochrane Review Methods was used. 11

# Search strategy and selection criteria

We searched the following databases: PubMed, Embase, Cochrane library, CNKI, VIP, and Wanfang) from in emperior to October 1, 2020. The main keywords were used: dexmedetomidine, randomized controlled trial (RCT), cleft palate, cleft lip, infant, children. Reference lists of identified studies were scanned for additional material.

#### Inclusion and exclusion criteria

Two authors (LP and YG) systematically and independently identified all the studies with predefined selection criteria. A third author (XL) arbitrated disagreements when conflicting selections occurred. Studies were included in this meta-analysis if they satisfied the following criteria:

1) Literature type: prospective, randomized-controlled studies; 2) Language: both English and Chinese; 3) subjects: children undergoing CLP repair; 4) Interventions: dexmedetomidine by any route of administration compared with any controls(including placebo and other drugs); 5) Outcomes: the primary outcome was the incidence of EA, secondary outcome was the need for postoperative rescue analgesia, and third outcomes were the incidence of adverse effects: PONV, respiratory adverse effects (breath holding, cough, degaturation and airway spasm), and

cardiovascular respiratory adverse effects (hypotension, bradycardia and postoperative bleeding).

Data collection and study appraisal

Two authors (JL and FL) independently extracted all the relevant information with a pre-specified data abstraction form. The following variables were collected: the name of the first author, publication year, country, publication language, number of patients, the protocol for administration method and dose, and outcomes. If the variables were not reported, we emailed the original authors to ask for the data.

Two authors (JL and FL) independently assessed the risk of bias basing on the Cochrane risk of bias tool, which considers adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assesser, incomplete reporting of outcome data, free of selective reporting, and free of other bias. In case of the conflicting evaluations, the third author (XL) was arranged to arbitrate disagreements.

# Quality of the evidence

The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE). We used GRADE profiler software version 3.2 to create the "Summary of findings" table, which includes the following outcomes: 1) Emergence agitation;2) Respiratory adverse events;3) The need for postoperative rescue analgesics; 4) Cardiovascular  $\frac{\alpha}{2}$  diverse events; and 5) Postoperative Nausea and vomiting.

 BMJ Open

# **Risk of Bias Across Studies**

Publication bias was assessed by using a funnel plot.

# **Statistical analysis**

bmjopen-2020-046798 on 16 August 2021. Download ftware (RevMan version 5.1, The meta-analysis was performed using the Cochrane Collaboration Review Manager https://training.cochrane.org/). We reported binary data as a risk ratio (RR) with 95% Confidence Interval (1). Chi square test (Mantel Haenszel method) was used to assess the heterogeneity between studies. An  $I^2 > 50\%$  and a P value < 0.10 was considered to indicate statistical heterogeneity. Subgroup analysis or sensitivity analysis was performed to analyze reasons of heterogeneity. Random effects model (Dersimonian and Laird method) was used when significant statistical or clinical heterogeneity was detected. P≤0.05 was considered to indicate a statistically significant difference for testing values of overall effect.

# Patient and public involvement

There was no patient or public involvement in this study.

# **RESULTS**

# **Study selection**

A total of 63 potentially relevant studies were identified. After excluding 50 studies, 13 studies including 104 children aged 3 months to 12 years were finally considered in this analysis. 12-24 The flow diagram of the literature search strategy was shown in Figure 1.

### **Description of studies**

The included studies were undertaken from 2012-2020 in four different countries: Egypt (three)<sup>12-14</sup>, Japen (one)<sup>16</sup>, India (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, the other six studies<sup>19-24</sup> were published in China dexmedetomidine is administered for its sedative effect in the form of intravenous<sup>15-21,23,24</sup>, intranasal<sup>22</sup> and perineural<sup>12-14</sup> administration.

Eleven studies 12,14-19,21-24 compared the effects of intravenous dexmedetomidine with saline, one study 20 compared the effects of intravenous dexmedetomidine with those of ketamine and fentanyl. One study 22 compared the effects of intranasal gexmedetomidine with saline. Two studies 12,14 compared the effects of perineural dexmedetomidine administration with placebo, and one study 25 compared the effects of perineural dexmedetomidine administration with those of dexamethasone. The characteristics of included studies were summarized in Table 1.

# Quality of the included studies

Nine studies 12,13,15-19,22,24 used a random allocation method. Four studies 13-15,17 described the allocation concealment in detail. Four studies 12,16-18 concretely explained their blinding methods. The risk of random allocation method was high in one study 20 and were unclear in the other three studies 14,21,23. The risk of allocation concealment were unclear and the risk of blinding were high in the other tudies. The risk of free of selective reporting were low in eight studies 12,14,17-20,22,23, unclear in one study 16 and high in other studies. For incomplete outcome data and free of other bias, most trials were judged as low risk of bias. The quality of included trials was summarized in Table 2 and supplementary file 1.

ed by copyright

/bmjopen-2020-046798 on

#### **Risk of Bias Across Studies**

The funnel plot was applied for assessing publication bias of studies in this meta-analysis in supplementar file 2. Due to the small number of studies, most of the publication bias of outcomes was unclear.

The overall quality of evidence based on the GRADE system was judged as moderate (The need for postoperative rescue analgesics,

The overall quality of evidence based on the GRADE system was judged as moderate (The need for postoperative rescue analgesics. Respiratory adverse events, and Cardiovascular adverse events), or low (EA and PONV) (Table 3).

#### **Emergence Agitation**

Eight trials<sup>15,18-24</sup> including 684 patients reported the incidence of EA. EA was evaluated by Ramsay score, Behavior score, Pediatric Anesthesia Emergence Delirium scale, or Aonos four-point scale. Dexmedetomidine administration(including intraversion and intranasal administration) showed a significant evidence of reducing EA when compared with saline<sup>15,18,19,21-24</sup> (RR, 0.19; 95% CI, 0.19 to 0.38; P<0.00001; I² = 62%) and all control groups<sup>15,18-24</sup> (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I² = 56%). We found different administration method of dexmedetomidine increased the clinical heterogeneity. Excluding the Yun2016 study<sup>22</sup> (intranasal administration), intravenogs dexmedetomidine administration showed a significant evidence of reducing emergence agitation when compared with saline<sup>15,18,19,21,23,24</sup> (RR, 0.24;95% CI, 0.13 to 0.44; P<0.00001; I²=40%), and when compared with all control groups <sup>15,18-21,23,24</sup> (RR, 0.24;95% CI, 0.14 to 0.41; P<0.00001; I²=29%). However, subgroup analysis showed no difference when dexmedetomidine was compared with intravenous fentanyl<sup>20</sup> (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19) and intravenous ketamine<sup>20</sup> (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19). (Fig.2).

#### The need for postoperative rescue analgesics

Five studies 12,14,17,18,23 including 293 pediatric patients reported that dexmedetomidine had a greater ana great

postoperatively (RR, 0.27; 95% CI, 0.10 to 0.73; P=0.01;  $I^2$ =84%). Basing on the two studies 12,14, there was no difference when perineural dexmedetomidine was compared with saline in the incidence of need for rescue analgesics at postoperative 2 (RR, 0.16; 95% CI, 0.00 to 33.36; P=0.50).

# Respiratory adverse events

Eight studies 15-21,23 including 794 pediatric patients reported the number of respiratory adverse events. We found that intravenous dexmedetomidine administration showed a significant lower incidence of respiratory adverse events when compared with saline (RR, 0.49; 95% CI, 0.31 to 0.78; P=0.002; I²=0%). Only one study (n=60) reported that dexmedetomidine showed a significant lower incidence of cough when compared with saline (RR, 0.45; 95% CI, 0.25 to 0.82; P=0.009). There were no differences when dexmedetomidine was compared with saline in the incidence of breath holding (RR, 1.29; 95% CI, 0.33 to 5.08; P=0.72), desaturation (RR, 0.41; 95% CI, 0.41; 95% CI, 0.16 to 1.08; P=0.07) and airway spasm (RR, 0.33; 95% CI, 0.07 to 1.54; P=0.16).

#### Cardiovascular adverse events

Three studies<sup>17,18,24</sup> including 880 pediatric patients reported the number of cardiovascular adverse events. We found that no differences when dexmedetomidine was compared with saline in the incidence of hypotension<sup>17,24</sup> (RR, 0.78; 95% CI, 0.30 to 2.07; P=0.62), bradycardia<sup>17,24</sup> (RR, 1.18; 95% CI, 0.61 to 2.28; P=0.62) and postoperative bleeding<sup>18,24</sup> (RR, 0.44; 95% CI, 0.18 to 1.11; P=0.08)

# Postoperative Nausea and vomiting

Eight trials<sup>13-15,17-20,23</sup> including 524 patients reported the incidence of PONV. Patients who received intraven administration

experienced no statistically significant increase in PONV when compared with saline  $^{14,15,17-19,23}$  (RR,  $0.90; \frac{9}{5}5\%$  CI, 0.40 to 2.06; P=0.81), and when compared with all control groups  $^{13-15,17-20,23}$  (RR, 0.92; 95% CI, 0.47 to 1.80; P=0.80). Also, subgroup analysis showed no difference when dexmedetomidine was compared with fentany  $^{120}$  (RR, 0.50; 95% CI, 0.06 to 4.15; P=0.52) , ketamine  $^{20}$  (RR, 0.50; 95% CI, 0.31 to 0.50; P=0.70).

#### **DISCUSSION**

#### Main findings

This meta-analysis revealed that perioperative administration of dexmedetomidine reduced the incidence of Ex in children undergoing CLP repair.

Pediatric patients receiving dexmedetomidine had lower need for rescue analgesics postoperative and less incodence of respiratory adverse events.

However, there were no significant differences in the risk of PONV and cardiovascular adverse events.

Although dexmedetomidine is not approved by U.S. Food and Drug Administration (FDA) for administration in children, it has been an authorized drug in Europe since September 2011.<sup>25</sup> It is increasingly used in the pediatric setting for various indications such as premedication, adjunct, sedative, intraoperative analgesia, and adjuvant, <sup>8</sup> but the efficacy was still controversial.

Our results found that both incidence of EA and the need for rescue analgesics postoperative green statistically decreased in the dexmedetomidine group as compared to the saline group. This was consistent with previous studies. 4,6,9,10 group was recent meta-analyses 30,31 found that the effects of dexmedetomidine in reducing risk of EA in children was superior to other drugs (including fentanyl, propofol, ketamine), which were inconsistent with our study. Numerous etiological factors (such as pre-existed anxiety, pain, age, type of girgical procedures, rapid awakening

/bmjopen-2020-046798

 and anesthetic technique) were considered to cause EA.<sup>26</sup> All of the included studies used sevoflurane anesthesia. It is widely believed that pain relief decreased the incidence of EA associated with sevoflurane general anesthesia. <sup>9,26</sup> It is known that dexmedetomidine shows dose-dependent effects on pain control and sedation. Reliable analgesic, sedative and neuroprotective effects could be main explanations for the effects of dexmedetomidine on EA.

Respiration is slightly affected by dexmedetomidine. 7-9 Our meta-analysis showed that dexmedetomidine would not influence the incidence of breath holding, desaturation and airway spasm. On the contrary, the incidence of cough and total respiratory adverse events were decreased in dexmedetomidine group. It was attributed to the residual sedation caused by the sedative effect of dexmedetomidine. Due to the rapid decreasing of concentration of sevoflurane during the recovery period, the fast awaken pediatric patients were in a highly sensitive state. It has minimal respiratory changes from the residual sedation, even extubation during the infusion of dexmedetomidine, in contrast to other sedatives. However, we should pay attention to that the strength of residual sedation was related to the early phase of post-anestigesia recovery time in postoperative anesthesia care unit.

As a selective  $\alpha 2$ -agonist, dexmedetomidine acted on the autonomic ganglia and performed its cardiovascular effect by decreasing sympathetic outflow and augmenting vagal activity, thus low infusion rates could cause bradycardia and hypotension while high doses could cause hypertension and aggravated bradycardia. Besides the dose, rapid injection may result in excessive hemodynamic externations, it is recommended that dexmedetomidine be administered slowly. Only two of thirteen included studies reported the incidence of bradycardia and hypotension. One study administrated dexmedetomidine as a loading dose over 10 min and followed by a maintenance infusion of  $\frac{1}{2}$ . 5 ug/kg/h until the last suture was applied, while the other study administrated dexmedetomidine as a maintenance infusion of 0.5 ug/kg/h intravenously after induction of anesthesia

until 20 min before the surgery finished. There was no significant difference in dexmedetomidine group  $\frac{2}{5}$  compared to placebo group. The hemodynamic stability owed to the method of low dose, slow injection and continuous infusion.

Few studies were focused on the effect of dexmedetomidine on PONV. Dexmedetomidine did not affect the incidence of PONV in our meta-analysis. This was consistent with a recent systematic review<sup>27</sup> in which dexmedetomidine intraoperative administration had no effect upon PONV during pediatric surgery, but it was inconsistent with a recent systematic review<sup>28</sup> in which dexmedetomidine was superior to placebo with a reduction in the need for an antiemetic in adults undergoing gynecological surgery. Another study also showed dexmedetomidine appeared to prevent postoperative vomiting after sevoflurane anesthesia for pediatric strabismus surgery. In their opinion, it is difficult to estimate the true incidence of nausea in younger children.<sup>29</sup> It may be the explanation for the difference effect of dexmedetomidine on PONV between children and adults.

# Limitations

There were still some limitations in our meta-analysis. First, only one study was designed with low risk of bas, the others were of moderate risk of bias. Second, more than ten dosages were used in the thirteen studies, including three methods of integanasal, perineural and intravenous administration. However, we did not use subgroup analysis for the administration doses. Third, not all studies reported in enough detail on their outcome measures which may prevent us from performing our analysis more formal.

#### **CONCLUSIONS**

Our findings demonstrate that perioperative administration of dexmedetomidine in children undergoing CLP epair efficiently decrease pain, EA, and respiratory adverse events. However, standardized usage and dosage need further investigation, and larger igorous studies need to be included.

#### **Author Contributions**

LP, YG and XL helped read and screen abstracts and titles of potentially relevant studies. JL, FL and XL helped read the retained papers and were responsible for extracting data and assessing their quality independently. DL helped design the study, conduct the study, analyse the data, and write the manuscript. JQ helped revise the paper with language. CH and CL helped design the study, conduct the study, analyse the data, and revise the manuscript. All authors contributed to conceptualize ideas, interpret findings and reviewed drafts of the manuscript.

Funding This work was supported by scientific research foundation of Wenzhou city in China grant number [Y2020592].

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license,

which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and an indication of whether changes were made is provided. See: https:// creative commons. org/ licenses/ by/ 4. 0

# **ORCID iD**

Chunwei Lian: https://orcid.org/0000-0003-4702-6147

Dengfeng Liu: https://orcid.org/0000-0001-9676-5996

#### REFERENCES

- 1. Somerville N, Fenlon S. Anaesthesia for cleft lip and palate surgery. *Contin Educ Anaesth Crit Care Pain* 2005; 5: 76-9.
- 2.Takemura H, Yasumoto K, Toi T, Hosoyamada A. Correlation of cleft type with incidence of perioperative respiratory complications in infants with cleft lip and palate. *Paediatr Anaesth* 2002; 12: 585-8.
- 3. Tremlett M. Anaesthesia for cleft lip and palate surgery. Curr Anaesth Crit Care 2004; 15: 309-16.
- 4.Dahmani S, Stany I, Brasher C, et al. Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies. *Br J Anaesth* 2010; 104: 216-23.
- 5.Nguyen C, Davies SM, Curtin CM, et al. Cleft palate surgery: An evaluation of length of stay, complications and costs by hospital type. *Cleft Palate Craniofac J* 2014; 51: 412-9.
- 6. Lin TF, Yeh YC, Lin FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth* 2009; 102: 117-22.
- 7.Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. Expert Opin Drug Saf 2011; 10: 55-66.
- 8. Sottas C E, Anderson B J. Dexmedetomidine: the new all-in-one drug in paediatric anaesthesia? Current opinion in anaesthesiology 2017, 30(4):441.
- 9.Cho H K, Yoon H Y, Jin H J, et al. Efficacy of dexmedetomidine for perioperative morbidities in pediatric fonsillectomy: A meta-analysis. *The Laryngoscope* 2017;128: E184-93.

- 10. Jun J H, Kim K N, Kim J Y, et al. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. Canadian Anaesthetists Society Journal 2017;64:947-61.
- 11. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (pdated march 2016). The Cochrane Collaboration, 2016. http:// handbook. cochrane. org/
- 12. Mostafa MF, Aal FAA, Herdan R, et al. Dexmedetomidine during suprazygomatic maxillary nerve black for pediatric cleft palate repair, randomized double-blind controlled study. *The Korean journal of pain* 2020; 33:81-9.
- 13. El-Emam EM, El Motlb EAA. Comparative Evaluation of Dexamethasone and Dexmedetomidine as Adju ants for Bupivacaine in Ultrasound-Guided Infraorbital Nerve Block for Cleft Lip Repair: A Prospective, Randomized, Double-Blind Study, Anesthesia, essays and researches 2019;13:354-8.
- 14. Obayah GM, Refaie A, Abdelazees M, et al. Addition of dexmedetomidine to bupivacaine for greater palatine nerve block prolongs postoperative analgesia after cleft palate repair. Eur J Anaesthesiol 2010; 27:280-4.
- 15. Peng W, Zhang T. Dexmedetomidine decreases the emergence agitation in infant patients undergoing cleft palate repair surgery after general anesthesia. BMC Anesthesiol 2015; 15:145-51.
- 16. Boku A, Hanamoto H, Niwa H, et al. Effectiveness of dexmedetomidine for emergence agitation in Sinfants undergoing palatoplasty: a randomized controlled trial. Brazilian journal of anesthesiology 2016; 66:37-43.
- 17, Surana P, Parikh DA, Patkar GA, Tendolkar BA. A prospective randomized controlled double-bind trial to assess the effects of otected by copyright dexmedetomidine during cleft palate surgery. Korean J Anesthesiol 2017; 70:633-41.

- 18. Luo K, Xu JM, Cao L, Gao J. Effect of dexmedetomidine combined with sufentanil on preventing emergence agitation in children receiving sevoflurane anesthesia for cleft palate repair surgery. Exp Ther Med 2017; 14:1775-82.
- 19. Mei D, Cong H, Jun L, et al. Effect of single-dose dexmedetomidine on recovery period after sevor uran anesthesia with spontaneous respiration in pediatric patients undergoing cleft lip and palate repair. Zhonghua Yi Xue Za Zhi. 2014; 94:1466-9. [Article in Chinese]
- 20. Xiao L, Long C, Jun F, Wen Z. Comparison of dexmedetomidine, ketamine and fentanyl in children undergoing cleft lip and palate surgery. *Zhejiang Practical Medicine* 2012; 17:173-5. [Article in Chinese]
- 21. Xi H, Zu H, Shou S, et al. The effect of recovery quality of dexmedetomidine for cleft lip and palate repair in children. Guangdong Medical Journal 2012; 33:2490-2. [Article in Chinese]
- 22. Yun L, Zhen L, Xu Y. Effects of intranasal dexmedetomidine for children undergoing cleft lip and palate pair surgery. *International Journal* of Stomatology 2016; 43:401-5. [Article in Chinese]
- 23. Ju P, Cheng Y, Ya J, Wan H. Efficacy of dexmedetomidine on recovery period in infants undergoing cleft lip and palate repair. Guangdong Medical Journal 2013; 34:1439-41. [Article in Chinese]
- Medical Journal 2013; 34:1439-41. [Article in Chinese]

  24. Jun P, Jun L, Jie L. Efficacy of dexmedetomidine on emergence agitation during recovery time in children after cleft lip and palate surgery. 2024 by gu *Zhejiang Traumatic Journal* 2018; 23:1250-1. [Article in Chinese]
- 25. Gerresheim G, Schwemmer U. Dexmedetomidine. *Anaesthesist* 2013; 62: 661–74.
- 26. Sun L, Guo R. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: A meta-analysis of randomized controlled otected by copyright trials. Acta Anaesthesiol Scand 2014; 58:642-50.

- 27. Bellon M, Le Bot A, Michelet D, et al. Efficacy of intraoperative dexmedetomidine compared with placeboost postoperative pain management: a meta-analysis of published studies. *Pain Ther* 2016; 5:63–80.
- a meta-analysis of published studies. *Pain Ther* 2016; 5:63–80.

  28. Liang X, Zhou M, Feng JJ, et al. Efficacy of dexmedetomidine on postoperative nausea and vomiting: a mega-analysis of randomized controlled trials. *Int J Clin Exp Med* 2015; 8: 12113-34.
- 29. CHEN J Y, JIA J E, LIU T J, et al. Comparison of the effects of dexmedetomidine, ketamine, and pacebo on emergence agitation after strabismus surgery in children. *Can J Anaesth* 2013,60: 385-92.
- 30. Tan D, Xia H, Sun S, et al. Effect of ancillary drugs on sevoflurane related emergence agitation in children undergoing ophthalmic surgery: a Bayesian network meta-analysis. *BMC Anesthesiol* 2019,19:138-49.

  31. Ni J, Wei J, Yao Y, et al. Effect of dexmedetomidine on preventing postoperative agitation in children: a meta-analysis. *PLoS One* 2015,10:
- 31. Ni J, Wei J, Yao Y, et al. Effect of dexmedetomidine on preventing postoperative agitation in children: meta-analysis. *PLoS One* 2015,10 e0128450.

# Figure captions:

Figure 1: Flow diagram of the literature search strategy

Figure 2: Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidence interval; RR: risk ratio.

Table1 Characteristics of the included randomized-controlled trials.

						02	
Study(year)	Country	Language	Age	N	Administration	Comparison	Outcomes
			(month/year)	(Dex/Control)	method	own	
Mostafa2020 <sup>12</sup>	Egypt	English	1-5y	15/15	perineural	Dex:0.5ug/leg	the incidence of
						Control: salme	need for rescue
						m.	analgesia
El-Emam2019 <sup>13</sup>	Egypt	English	3-6m	50/50	perineural	Dex:0.5ug/kg	the incidence of
				-/ h		Control: 0.1ang/kg DA	PONV
Obayah2010 <sup>14</sup>	Egypt	English	$11.7 \pm 2.4 \text{m}$	15/15	perineural	Dex:1ug/kgg	the incidence of
			$12\pm 2.7m$			Control: salme	PONV, need for
						omj.c	rescue
						) )	analgesia
Peng2015 <sup>15</sup>	China	English	3-24m	20/20	intravenous	Dex:0.8ug/lg/min	the incidence of
						(continuous	EA, PONV,
						intrave <del>n</del> ous infusion	airway spasm
						after induction)	
						Control: salme	
Boku2015 <sup>16</sup>	Japan	English	10-14m	35/35	intravenous	Dex:6ug/kg/h (10 min	the incidence of
						before the end of the	desaturation
						surgery for 10 min)	
						+0.4uggkg/h	
						(continuous	
						у с	

						16798		
			1.26±0.24	у		inducti\(\vartheta\)n) +0.5ug/kg/h	EA,	PONV,
			1.25±0.23	y		(continuous	desatur	ation
						intrave fous infusion		
						after in ubation)		
						Control 1:2 kg/kg (during		
						inducti <mark>o</mark> n)		
						+0.5m <b>હ</b> /kg/h		
						(conting ous		
						intravenous infusion		
				9er/6		after ingubation)		
						ketamine		
						Control 2:3 kg (during		
						induction) + 1ug/kg		
						(intermattent		
						administration twice)		
Xi2012 <sup>21</sup>	China	Chinasa	1 2	15/15		fentany	4le a ine ai	idence of
X1201221	China	Chinese	1-3y	15/15	intravenous	Dex:1ug/kgg (30min before surgers finish		idence of
						surgery finish for 10 min)		holding,
						Control: saline	desatur	_
						Control. Sansic	airway	-
Yun2016 <sup>22</sup>	China	Chinese	6m-3y	60/60	intranasal	Dex:2ug/kg (30min before		idence of
1 4112010	Cililia	Cililese	om sy	00/00	Titt did di	surger finish)	EA	dence of
						Control: salime	211	
Ju2013 <sup>23</sup>	China	Chinese	4m-3y	40/40	intravenous	Dex:0.5ug/kg (10min before	the inci	idence of
			J			surger start for 10min)		eed for
						ьу		
						CO		

Table 2 Individual Randomized Controlled Trial Methodological Quality.

						ον	
Study (year)	Adequate sequence generation	Allocation concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Incomplete outcome data addressed	Free of selective reporting	Free of other bias
Mostafa2020 <sup>12</sup>	yes	?	yes	yes	yes	<u> </u>	yes
El-Emam2019 <sup>13</sup>	yes	yes	No	yes	yes	Næ	yes
Obayah2010 <sup>14</sup>	?	yes	No	No	yes	yee//bggjoggen.bmj.coms yeen.bmj.coms Yeev	yes
Peng2015 <sup>15</sup>	yes	yes	No	No	No	Nog	yes
Boku2015 <sup>16</sup>	yes	?	yes	yes	yes	? 🚊	yes
Surana2017 <sup>17</sup>	yes	yes	yes	yes	yes	yes	yes
Luo2017 <sup>18</sup>	yes	?	yes	yes	yes	yeş / ye <u>ş</u> .	No
Mei2014 <sup>19</sup>	yes	?	No	No	yes	∕ ye <u>\$</u> .	yes
Xiao2012 <sup>20</sup>	No	?	No	No	yes	yes∞	yes
Xi2012 <sup>21</sup>	?	?	No	No	yes	Nog	yes
Yun2016 <sup>22</sup>	yes	?	yes	No	yes	ye <mark>\$</mark>	yes
Ju2013 <sup>23</sup>	?	?	No	No	yes	ye€	yes
Jun2018 <sup>24</sup>	yes	?	No	No	yes	No <sup>∰</sup>	yes

Yes=low risk of bias; No=high risk of bias; ?=unclear risk of bias.

#### Dexmedetomidine for cleft lip and palate repair

		ВМЈ Ор	en		/bmjopen-2020-046798 on 16 August 2021. Down	
Table 3 Summary of findings for the mai	n outcomes			•	6 August 2021. Down	
Dexmedetomidine for cleft lip and palate repair	<b>U</b> /- ,				noade	
Patient or population: patients with cleft lip and pal Settings: surgery Intervention: Dexmedetomidine	ate repair				oaded from http://bm	
Outcomes	Illustrative comp Assumed risk Control	carative risks* (95% CI)  Corresponding risk  Dexmedetomidine	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Emergence agitation	Study populatio	87 per 1000 (46 to 165)	RR 0.19 (0.10 to 0.36)	684 (8 studies)	90 ⊕⊕⊖⊖ Pow <sup>1,2,3,4,5</sup> 148	
Respiratory adverse events	Study populatio	50 per 1000 (32 to 80)	RR 0.49 (0.31 to 0.78)	794 (8 studies)		
The need for postoperative rescue analgesics	Study populatio	160 per 1000 (59 to 432)	RR 0.27 (0.1 to 0.73)	293 (5 studies)	⊈.  Protected by co	

om/ on April 18, 2024 by

guest. Protected by copyright

					3798
Cardiovascular adverse events	Study population	n	RR 0.83	880	9
	105 per 1000	87 per 1000	(0.52 to 1.31)	(3 studies)	0 moderate¹ >
		(55 to 138)			ngus
Postoperative Nausea and vomiting	Study population	n	RR 0.92	524	202 02
	63 per 1000	58 per 1000	(0.47 to 1.80)	(8 studies)	i⊇ low¹ □
		(30 to 113)			o Vn

\*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% ponfidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval: RR: Risk ratio:

GRADE Working Group grades of evidence


High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.


Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

- <sup>1</sup> Allocation concealment and/or blinding of outcome assessors unclear/inadequate in 50% or more of the included studies
- <sup>2</sup> Significant heterogeneity (I 2 > 50%) is partially explained by different administration method, dose and comparators.
- <sup>3</sup> Use of several different scoring criterias to evaluate emergence agitation.
- <sup>4</sup> a dose response gradient was present
- <sup>5</sup> RR >5 or <0.2
- <sup>6</sup> RR >2 or <0.5



Flow diagram of the literature search strategy  $82x73mm (300 \times 300 DPI)$ 



Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidence interval; RR: risk ratio.

205x114mm (300 x 300 DPI)

# Risk of bias

Mostafa2020<sup>12</sup> (ClinicalTrials.gov ID: NCT03412474).

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	A computer-generated program of
generation (selection	0	random numbers
bias)		
Allocation concealment	unclear	Not mentioned
(selection bias)		
Blinding of participants	Low risk	Neither the doctors (investigators) nor the
and personnel		patients' guardians or
(performance bias)		even the children themselves were aware
All outcomes		of the group al-
		location and the drug received. One
		anesthesiologist not
		involved in the block implementation or
		the data collection, prepared all the study
		solutions.
Blinding of outcome	Low risk	While a third, blinded to the previous
assessment (detection		protocol, was responsible

bias)		only for data collection.
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 80 patients
Other bias	Low risk	Groups well balanced

El-Emam2019<sup>13</sup> Clinical Trials.gov (NCT03480607)

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	computer-generated randomization
generation (selection		numbers
bias)		
Allocation concealment	Low risk	a closed-seal envelope
(selection bias)	•	
Blinding of participants	High risk	The principal investigator prepared the
and personnel	0	drug and performed the block
(performance bias)		
All outcomes		
Blinding of outcome	Low risk	the person observing and recording the
assessment (detection		parameters was blinded to the study.
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	High risk	The primary outcome was to compare
(reporting bias)		both groups regarding time to first rescue
		analgesic, while the primary outcomes in
		the pre-registration site were

		postoperative	FLACC	scale	and
		postoperative s	edation sco	re.	
Other bias	Low risk	Groups well bal	anced		



# Obayah2010<sup>14</sup>

Bias	Authors'	Support for judgement

	judgement	
Random sequence	Unclear risk	"randomly allocated", no details
generation (selection		
bias)		
Allocation concealment	Low risk	The randomization was achieved by the
(selection bias)		opening of a sealed envelope by the
0	4	attending physician
Blinding of participants	High risk	Not mentioned
and personnel		
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 30 patients
Other bias	Low risk	Groups well balanced



Peng2015<sup>15</sup> Chinese Clinical Trial Register (ChiCTR-TRC-13003865).

Bias	Authors'	Support for judgement
	judgement	

Random sequence	Low risk	Randomly divided with a computer-
generation (selection		generated sequence of numbers
bias)		
Allocation concealment	Low risk	a sealed envelop
(selection bias)		
Blinding of participants	High risk	Not mentioned
and personnel		
(performance bias)	6	
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		<b>L</b> .
All outcomes		
Incomplete outcome	High risk	The actual sample was 40 while the
data (attrition bias)		planned sample in the pre-registration site
All outcomes		was 60.
Selective reporting	High risk	The primary outcome was to compare
(reporting bias)		both groups regarding emergence
		agitation and time about recovery
		parameters while the primary outcomes in
		the pre-registration site were heart rate
		and blood pressure.

Other bias	Low risk	Groups well balanced



Boku2015<sup>16</sup> (UMIN 000009869) http://upload.umin.ac.jp.

Bias Authors'	Support for judgement
---------------	-----------------------


	judgement	
Random sequence	Low risk	A computer-generated
generation (selection		random number table
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	Low risk	The patient's parents and the attending
and personnel	0	anesthesiologist were blinded to the group
(performance bias)		allocation
All outcomes		
Blinding of outcome	Low risk	Data for each patient were
assessment (detection		obtained by
bias)		the blinded anesthesiologist.
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Unclear risk	Do not get the protocol
(reporting bias)		
Other bias	Low risk	Groups well balanced



## Surana201717

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	a computer-generated randomized chart
generation (selection		

bias)		
Allocation concealment	Low risk	The random group
(selection bias)		assignments were enclosed in a sealed
		opaque envelope
Blinding of participants	Low risk	the surgeons, the patients, and the
and personnel		anesthesiologist in the post-anesthesia
(performance bias)	8	care unit (PACU) were all blinded
All outcomes	6	
Blinding of outcome	Low risk	Data was recorded by a blinded observer.
assessment (detection	2	
bias)		
All outcomes		7.
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		7
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 60 patients
Other bias	Low risk	Groups well balanced



## Luo201718

Bias	Authors'	Support for judgement
	judgement	
Random sequence Low risk		a computer-generated table of
generation (selection		random numbers
bias)		

Allocation concealment	Unclear risk	Not mentioned.		
(selection bias)				
Blinding of participants	Low risk	All pharmacological agents used in the		
and personnel		present study were prepared and		
(performance bias)		administrated by the anesthesiologists		
All outcomes		who were blinded to the details of the		
O		study.		
Blinding of outcome	Low risk	Pediatric Anesthesia Emergence Delirium		
assessment (detection	0	and CHIPPS scores were documented by		
bias)		а		
All outcomes		well-trained PACU nurse who was blinded		
		to the study.		
Incomplete outcome	Low risk	4 patients from group DS and 3 patients		
data (attrition bias)		from group SF were excluded from the		
All outcomes		analysis		
Selective reporting	Low risk	The authors provided results for all		
(reporting bias)		measurements for 93 patients		
Other bias	High risk	Groups well balanced. Not in intention-to-		
		treat: Of the 100 patients admitted to the		
		study, 7 were later excluded by the		
		authors for the reasons listed in table II,		

	leaving	data	from	93	patients	for
	consider	ation				



#### Mei2014<sup>19</sup>

Bias	Authors'	Support for judgement
	judgement	

Random sequence	Low risk	a table of random numbers, no detail
generation (selection		
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)	6	
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		<b>L</b> .
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 60 patients
Other bias	Low risk	Groups well balanced.



## Xiao201220

Bias		Authors'	Support for judgement	
		judgement		
Random	sequence	High risk	randomized according to the operation	


generation (selection		time sequence
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		<b>L</b> .
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 54 patients
Other bias	Low risk	Groups well balanced.



## Xi201221

Bias		Authors'	Support for judgement
		judgement	
Random	sequence	Unclear risk	Random mentioned, no detail
generation (selection			

bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection	0	
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		7
Selective reporting	High risk	Lack of complications, such as
(reporting bias)		postoperative hoarseness, nausea and
		vomiting
Other bias	Low risk	Groups well balanced.



## Yun2016<sup>22</sup>

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	a table of random numbers, no detail
generation (selection		
bias)		
Allocation concealment	Unclear risk	Not mentioned.

(selection bias)		
Blinding of participants	Low risk	A blinded anesthesia nurse prepared and
and personnel		administrated drugs
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)	6	
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		<b>L</b> .
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 120 patients
Other bias	Low risk	Groups well balanced.



Ju2013 <sup>23</sup>		
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Unclear risk	Mentioned random, no detail
generation (selection		
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.

and personnel		
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)	0	
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 80 patients
Other bias	Low risk	Groups well balanced.

## Jun2018<sup>24</sup>

Jun2018 <sup>24</sup>		
Bias	Authors'	Support for judgement
	judgement	7
Random sequence	Low risk	Compute randomized
generation (selection		
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)		

All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		
Selective reporting	High risk	The secondary outcomes were to
(reporting bias)		compare both groups regarding
		extubation time and incision bleeding
		which were not mentioned in method.
Other bias	Low risk	Groups well balanced.
		7




Figure 1 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.1 emergence agitation.




Figure 2 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.2 postoperative nausea and vomiting.




Figure 3 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.3 complication in respiration.

TO TORREST ONLY




Figure 4 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.4 complication in circulation.




Figure 5 Funnel plot of comparison: dexmedetomidine vs control, outcome:1.5 postoperative analgesia rescue.

Page 62 of 62

46 47

## PRISMA 2009 Checklist

		0 -0	
Section/topic	#	Checklist item	Reported on page #
TITLE		16	1-2
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1-2
ABSTRACT		ust 2	3-4
2 Structured summary 3 4	2	Provide a structured summary including, as applicable: background; objectives; data sources study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION		oad	5
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
S Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS		//bπ	6-8
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study guthors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
2 Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g.e.e <sup>2</sup> ) for each metagonal spen.bmj.com/site/about/guidelines.xhtml	6-7

BMJ Open



45 46 47

## PRISMA 2009 Checklist

Page 63 of 62			BMJ Open 360 br	
1 2 3	PRISMA 2009 Checklist		BMJ Open  Checklist  Page 1 of 2	
4		Page 1 of 2		
5 6 7	Section/topic	#	Checklist item 0798 on 779	Reported on page #
8 9	Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-8
10 11 11	Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
13	RESULTS			8-12,21-27
14 15 16	Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
17	Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOs, follow-up period) and provide the citations.	9,21-24
19	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9,25
2	Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9,10
23	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-12
25	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9-10,26-27
26	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
28	DISCUSSION		Ar	12-15
30	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
33	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., ingomplete retrieval of identified research, reporting bias).	14
3! 3!	Conduciono	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14,15
37	FUNDING		Prot	15
38 39	Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

41
42 From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

# **BMJ Open**

## Efficacious of dexmedetomidine in children undergoing cleft lip and palate repair: a systematic review and meta-analysis

Journal:	BMJ Open			
Manuscript ID	bmjopen-2020-046798.R1			
Article Type:	Original research			
Date Submitted by the Author:	21-Feb-2021			
Complete List of Authors:	Liu, Dengfeng; School and Hospital of Stomatology, Wenzhou Medical University, Department of Oral Maxillofacial Surgery Pan, Li; School and Hospital of Stomatology, Wenzhou Medical University, Department of Oral Maxillofacial Surgery Gao, Yin; School and Hospital of Stomatology, Wenzhou Medical University, Department of Oral Maxillofacial Surgery Liu, Jiefan; School and Hospital of Stomatology, Wenzhou Medical University, Department of Oral Maxillofacial Surgery Li, Feng; School and Hospital of Stomatology, Wenzhou Medical University, Department of Oral Maxillofacial Surgery Li, Xiangwei; Air Force Health Care Center For Special Service Hangzhou, Department of Rehabilitation Quan, Jiale; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Department of Anesthesiology and Perioperative Medicine HUANG, CONGCONG; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Department of Anesthesiology and Perioperative Medicine Lian, Chunwei; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Department of Anesthesiology and Perioperative Medicine			
<b>Primary Subject Heading</b> :	Surgery			
Secondary Subject Heading:	Anaesthesia, Paediatrics, Dentistry and oral medicine			
Keywords:	ORAL & MAXILLOFACIAL SURGERY, Paediatric anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS			

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Efficacious of dexmedetomidine in children undergoing cleft lip and palate repair: a systematic reviewand meta-analysis

Dengfeng Liu<sup>1</sup>, Li Pan<sup>1</sup>, Yin Gao<sup>1</sup>, Jiefan Liu<sup>1</sup>, Feng Li<sup>1</sup>, Xiangwei Li<sup>3</sup>, Jiale Quan<sup>2</sup>,

Congcong Huang<sup>2\*</sup>, Chunwei Lian<sup>2\*\*</sup>

- 1.Department of Oral Maxillofacial Surgery, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
- 2.Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical

University; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.

3. Department of Rehabilitation, Air Force Health Care Center For Special Service Hangzhou, Hangzhou, Zhejiang, P.R. China.

/bmjopen-2020-046798 on

## **ABSTRACT**

Objective To systematically assess the efficacy and safety of dexmedetomidine as an anaesthesia adjuvant for cleft lip and palate (CLP) repair in children.

**Design** Systematic review and meta-analysis.

Data sources PubMed, Embase, Cochrane, CNKI, VIP, and Wanfang (up to Oct 2020). Studies in languages 5 ther than English and Chinese were excluded.

Eligibility criteria for selecting studies Randomized controlled trials (RCTs) evaluating the impact of dexmediation (EA), the need for postoperative rescue analgesics, postoperative nausea and vomiting (PONV), and other adverse events in paediatric patients during CLP repair.

Data extraction and synthesis The quality of evidence was assessed by using the Cochrane Review Methods and the Grading of Recommendations Assessment, Development, and Evaluation approach. Data were screened, extracted and assessed by two independent authors. Outcomes reported as a risk ratio (RR) with a 95% confidence interval (CI). A random effects model was used when heterogeneity was detected. Results Thirteen studies including 1040 children met the inclusion criteria. The incidence of EA was significantly decreased in the dexmedetomidine group (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I<sup>2</sup>=56%) as compared to the control group. Paediatric patients receiving dexmedetomidine had lower postoperative analgesic requirements (RR, 0.27; 95% CI, 0.10 to 0.73; P=0.0 \( \) I<sup>2</sup>=84%) and a lower incidence of respiratory adverse events (RR, 0.49; 95% CI, 0.31 to 0.78; P=0.003;  $I^2$ =0%). There were no significant differences in the risk of PONV and otected by copyright cardiovascular adverse events.

Conclusions There was a lack of high-quality studies in this field. Perioperative administration of dexidedetomidine reduced the need for postoperative rescue analgesics and the incidence of EA in children without side effects undergoing CLP repair. However, further verification with larger samples and more high quality RCTs are needed.

Keywords children, dexmedetomidine, cleft lip and palate repair, pain, emergence agitation

#### **ARTICLE SUMMARY**

## Strengths and limitations of this study

Studies in both English language and Chinese language were included.

This is a comprehensive systematic review that identified the benefits of dexmedetomidine in children under going CLP repair.

Heterogeneity was observed in the doses, timing of administration and evaluation methods for the outcomes across studies.

For some comparisons, the numbers of trials included and outcomes reported were small.

The low quality of the included studies impedes us from drawing firm conclusions.

Word account: 3349

/bmjopen-2020-046798 on 1

## **INTRODUCTION**

Cleft lip and palate (CLP) are widespread congenital disfigurement requiring surgical correction early in life. 1 Parly surgery is important to alleviate feeding difficulty, reduce airway complications and improve phonation problems.<sup>2</sup> However, cleft palate repair is needed to dissect the soft and hard palates and may result in significant postoperative oropharyngeal pain and bleeding. High-dose opioids with sevoflurane anaesthesia are commonly used to block the autonomic response,<sup>3</sup> while many paediatric patients suffer from a high risk of espiratory depression, postoperative emergence agitation (EA), postoperative nausea and vomiting (PONV), a prolonged hospital stay and increased hospital costs. 4-6

Dexmedetomidine is a potent α2 adrenoreceptor agonist with sedative, anxiolytic, sympatholytic and analgesic properties. It alleviated the autonomic response to surgery and ensured a stable haemodynamic state without significant respiratory depression. One previous study had demonstrated that dexmedetomidine is helpful as a valuable adjunct for multiple applications and is increasingly used in paediatric anaesthesia settings. A meta-analysis recently showed that perioperative administration of dexmedetomidine can provide pain and agitation relief without side effects in children undergoing adenotonsillectomy. Another meta-analysis 10 found that intranasal dexmede omidine provided more satisfactory sedation at parent separation and reduced the need for postoperative rescue analgesics in paediatric patients. However, evidence in the existing literature was insufficient to fully support the effective and safe use of dexmedetomidine in children undergoing CLP repair.

Therefore, our study aimed to identify the efficacy and safety of dexmedetomidine in children during CLP repair. We performed a meta-analysis by guest. Protected by copyright of randomized controlled trials comparing dexmedetomidine with controls.

/bmjopen-2020-046798 on

#### **METHODS**

We evaluated the efficacy and safety of dexmedetomidine administration during CLP repair in children. A sæstematic review approach based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and the Cochrane Review Methods was used. 11

#### Search strategy and selection criteria

We searched the following databases from inception to October 1, 2020: PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang. The main keywords used were: dexmedetomidine, randomized controlled trial (RCT), cleft palate, cleft lip, infan\( \beta \) and children. The reference lists of identified studies were searched for additional eligible studies. (search strategy of PubMed as supplementary lile1)

#### Inclusion and exclusion criteria

Two authors (LP and YG) systematically and independently identified all the studies using predefined selection criteria. A third author (XL) resolved disagreements when conflicting selections occurred. Studies were included in this meta-analysis it they met the following criteria: 1) Literature type: prospective, randomized controlled studies; 2) Language: both English and Chinese; 3) Subjects: children undergoing CLP repair; 4) Interventions: dexmedetomidine by any route of administration compared with any controls(including sagne and other drugs); 5) Outcomes: the primary outcome was the incidence of EA, secondary outcome was the need for postoperative rescue analgesia, and third outcomes were the incidence of adverse effects: PONV, respiratory adverse effects (breath holding, cough, desaturation and  $\frac{\alpha}{2}$  airway spasm), and cardiovascular otected by copyright adverse effects (hypotension, bradycardia and postoperative bleeding).

/bmjopen-2020-046798 on 16 Aug

# Data collection and study appraisal

Two authors (JL and FL) independently extracted all the relevant information with a prespecified data abstraction form. The following variables were collected: the name of the first author, publication year, country, publication language, other anaesthetic agents, number of patients, protocol for administration method and dose, and outcomes. If the variables were not reported, we emailed the origina authors to ask for the data.

Two authors (JL and FL) independently assessed the risk of bias based on the Cochrane risk of bias tool, which considers the following aspects: adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessor, incomplete reporting of outcome data, free of selective reporting, and free of other bias. In case of conflicting evaluations, a third author (XL) was consulted to resolve disagreements.

### Quality of the evidence

Quality of the evidence

The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE). We used GRADE profiler software version 3.2 to create the "Summary of findings" table, which includes the following outcomes: 1) EA; 2) respiratory adverse events; 3) the need for postoperative rescue analgesics; 4) cardiovascular adverse events; and 5) PONV.

### Risk of bias across studies

Publication bias was assessed by using a funnel plot.

Statistical analysis

The meta-analysis was performed using Cochrane Collaboration Review Manager Software (RevMan version 5.1, https://training.cochrane.org/). We reported binary data as a risk ratio (RR) with a 95% confidence interval (CI). The chi square test (Mantel Baenszel method) was used to assess the heterogeneity between studies. An  $I^2 > 50\%$  and a P value < 0.10 were considered to indicate statistical eterogeneity. Subgroup analysis or sensitivity analysis was performed to analyse reasons for heterogeneity. A random effects model (DerSimonian and Laird method) was used when significant statistical or clinical heterogeneity was detected. P≤0.05 was considered to indicate a statistically significant difference for testing values of overall effect.

# Patient and public involvement

There was no patient or public involvement in this study.

### **RESULTS**

#### **Study selection**

A total of 63 potentially relevant studies were identified. After excluding 50 studies, 13 studies including 104\P children aged 3 months to 12 years were finally included in this analysis. 12-24 The flow diagram of the literature search strategy is shown in Fig 18 to 50 to 5

#### **Description of studies**

The included studies were undertaken from 2012-2020 in four different countries: Egypt (three)<sup>12-14</sup>, Japan (one)<sup>16</sup>, India (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in China (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>.

Eleven studies 12,14-19,21-24 compared the effects of intravenous dexmedetomidine with saline, and one study 20 compared the effects of intravenous dexmedetomidine with those of ketamine and fentanyl. One study 22 compared the effects of intraval as all dexmedetomidine with saline. Two studies 12,14 compared the effects of perineural dexmedetomidine administration with saline, and one study 3 compared the effects of perineural dexmedetomidine administration with saline administration with those of dexamethasone. The characteristics of the included studies are summarized in Table 1.

# Quality of the included studies

Nine studies <sup>12,13,15-19,22,24</sup> used a random allocation method. Four studies <sup>13-15,17</sup>described the allocation concealment in detail. Four studies <sup>12,16-18</sup> concretely explained their blinding methods. The risk of the random allocation method was high in one study <sup>30</sup> and was unclear in the other three studies <sup>14,21,23</sup>. The risk of allocation concealment was unclear and the risk of blinding was high in the other studies. The risk of free of selective reporting was low in eight studies <sup>12,14,17-20,22,23</sup>, unclear in one study <sup>16</sup> and high in other studies. For incomplete poutcome data and free of other bias, most trials were judged as having a low risk of bias. The quality of the included trials is summarized in Table 2, Fig 2 and supplementary file 2.

#### Risk of bias across studies

A funnel plot was applied to assess the publication bias of the studies in this meta-analysis in supplementar file 3. Due to the small number of studies, most of the publication bias of outcomes was unclear.

The overall quality of evidence based on the GRADE system was judged as moderate (the need for postoperative rescue analgesics, respiratory adverse events, and cardiovascular adverse events), or low (EA and PONV) (Table 3).

# **Emergence agitation**

Eight trials<sup>15,18-24</sup> including 684 patients reported the incidence of EA. EA was evaluated by the Ramsage score, behaviour score, Pediatric Anesthesia Emergence Delirium scale, or Aonos four-point scale. Dexmedetomidine administration (including intravenous and intranasal administration) showed significant evidence of reduced EA when compared with saline<sup>15,18,19,21-24</sup> (RR, 0.19; 95% CI, 0.10 to 0.38; P<0.00001; I<sup>2</sup> = 62%) and all control groups<sup>15,18-24</sup> (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I<sup>2</sup> = 56%). We found that different administration methods of dexmedetomidine increased the clinical heterogeneity. Excluding the 2016 study by Yun<sup>22</sup> (intranasal administration), intravenous dexmedetomidine administration showed a significant evidence of reduced EA when compared with saline<sup>15,88,19,21,23,24</sup> (RR,0.24;95% CI, 0.13 to 0.44; P<0.00001; I<sup>2</sup>=40%), and when compared with all control groups <sup>15,18-21,23,24</sup> (RR, 0.24;95% CI, 0.14 to 241; P<0.00001; I<sup>2</sup>=29%). However, subgroup analysis showed no difference when dexmedetomidine was compared with intravenous fentanyl (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19) and intravenous ketamine<sup>20</sup> (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19). (Fig 3).

# The need for postoperative rescue analgesics

Five studies 12,14,17,18,23 including 293 paediatric patients reported that dexmedetomidine had a greater analgest effect than saline postoperatively (RR, 0.27; 95% CI, 0.10 to 0.73; P=0.01; I<sup>2</sup>=84%). In contrast to the two studies that used perinetral administration 12,14, intravenous

dexmedetomidine administration<sup>17,18,23</sup> showed a significant analgesic effect when compared with saline<sup>9</sup>(RR, 0.26; 95% CI, 0.16 to 0.44; P<0.00001; I<sup>2</sup>=0%). Subgroup analysis showed that there was no difference when perineural dexmedetomid le <sup>12,14</sup> was compared with saline in the incidence of need for rescue analgesics at postoperative 24 h (RR, 0.16; 95% CI, 0.00 to 33.36; P=0.50). Respiratory adverse events

Eight studies<sup>15-21,23</sup> including 794 paediatric patients reported the number of respiratory adverse exents. We found that intravenous dexmedetomidine administration showed a significantly lower incidence of respiratory adverse events than saline administration (RR, 0.49; 95%) CI, 0.31 to 0.78; P=0.003; I<sup>2</sup>=0%). Only one study<sup>19</sup> (n=60) reported that dexmedetomidine showed a significantly lower incidence of cough than saline (RR, 0.45; 95% CI, 0.25 to 0.82; P=0.009). There were no differences when dexmedetomidine was compared with saline in the incidence of breath holding<sup>18,19,21</sup> (RR, 1.35; 95% CI, 0.31 to 5.92; P=0.69; I<sup>2</sup>=0%), desaturation<sup>16,17,19-21,23</sup> (RR, 0.47; 98% CI, 0.17 to 1.29; P=0.14; I<sup>2</sup>=0%) or airway spasm<sup>15,19,21</sup> (RR, 0.33; 95% CI, 0.07 to 1.54; P=0.16; I<sup>2</sup>=0%).

#### Cardiovascular adverse events

Three studies 17,18,24 including 880 paediatric patients reported the number of cardiovascular adverse events. We found that no differences when dexmedetomidine was compared with saline in the incidence of hypotension<sup>17,24</sup> (RR, 1.18; 95% CI, 0.61 to 2.28; P=0.62), bradycardia<sup>17,24</sup> (RR, 0.78; 95% CI, 0.30 to 2.07; P=0.62) or postoperative bleeding  $^{18,24}$  (RR, 0.45; 95% CI, 0.17 to 1.15; P=0.09; E=0%).

# **Postoperative Nausea and vomiting**

Eight trials 13-15,17-20,23 including 524 patients reported the incidence of PONV. Patients who received dexmede midine administration experienced

no statistically significant increase in PONV when compared with saline 14,15,17-19,23 (RR, 0.95; 95% CI, 0.4 to 2.19; P=0.91; I<sup>2</sup>=0%), and when compared with all control groups <sup>13-15,17-20,23</sup> (RR, 0.96; 95% CI, 0.48 to 1.90; P=0.90; I<sup>2</sup>=0%). Subgroup an all showed that there was also no difference when perineural dexmedetomidine was compared with control groups 13,14. Additionally, another subgroup analysis showed no difference when intravenous dexmedetomidine was compared with fentanyl<sup>20</sup> (RR, 0.50; 95% CI, 0.06 to 4.15; P=0.52) and ketamine <sup>20</sup> (RR, 0.50; 95% CI, 0.06 to 4.15; P=0.52), or when perineural dexmedetomidine was compared with dexamethasone (RR, 1.33; 95% CI, 0.31 to 5.65; P=0.70).

#### **DISCUSSION**

#### **Main findings**

This meta-analysis revealed that perioperative administration of dexmedetomidine reduced the incidence of Ex in children undergoing CLP repair. Paediatric patients receiving dexmedetomidine had a lower need for rescue analgesics postoperatively and a lower incidence of respiratory adverse events. However, there were no significant differences in the risk of PONV and cardiovascular adverse events.

Although dexmedetomidine is not approved by U.S. Food and Drug Administration (FDA) for administration in children, it has been an authorized drug in Europe since September 2011.25 It is increasingly used in the pediatric setting for variou\(\tilde{\gamma}\) indications such as premedication, adjunct, sedative, intraoperative analgesia, and adjuvant therapy<sup>8</sup> but the efficacy is still controversial.

Our results found that both the incidence of EA and the need for rescue analgesics postoperatively  $\frac{\varphi}{W}$  ere significantly decreased in the dexmedetomidine group as compared to the saline group. This was consistent with previous studies. 4,6,9,10 \$\vec{\pi}\$ wo recent meta-analyses 26,27 found

/bmjopen-2020-046798

ed by copyright

 that the effects of dexmedetomidine on reducing the risk of EA in children were superior to those of other drugs (including fentanyl, propofol, ketamine), which was inconsistent with our study. Numerous aetiological factors (such as pre-existing maintainty, pain, age, type of surgical procedures, rapid awakening and anaesthetic technique) were considered to cause EA.<sup>28</sup> All of the included studies used sevoflurane anaesthesia. It is widely believed that pain relief of decreases the incidence of EA associated with sevoflurane general anaesthesia. 9,28 Dexmedetomidine shows dose-dependent effects on pain control and sedation. Reliable analgesic, sedative and neuroprotective effects could be the main explanations for the effects of dexmedetomidine on EA.

Respiration is slightly affected by dexmedetomidine. Our meta-analysis showed that dexmedetomidine did not influence the incidence of breath holding, desaturation or airway spasm. In contrast, the incidence of cough and total respiratory adverse events were decreased in the dexmedetomidine group. This was attributed to the residual sedation caused by the sedative effect of dexmedetomidine. Due to the rapid decrease in the concentration of sevoflurane during the recovery period, rapidly awakening paediatric patients were in a siighly sensitive state. It has minimal respiratory changes from the residual sedation, even extubation during the infusion of dexmedetomidine, in contrast to other sedatives. However, we should pay attention to the fact that the strength of residual sedation was related to the early phase of postanaesthesia recovery time in postoperative anaesthesia care unit.

As a selective  $\alpha 2$ -agonist, dexmedetomidine acts on the autonomic ganglia and exerts its cardiovascular effet by decreasing sympathetic outflow and augmenting vagal activity, thus low infusion rates could cause bradycardia and hypotension while high loses could cause hypertension and aggravate bradycardia. In addition to the dose, rapid injection may result in excessive haemodynamic alterations, and it is recommended that dexmedetomidine be administered slowly. Only two of thirteen included studies reported the incidence of bradycardia and hypotension. One study

administered dexmedetomidine as a loading dose over 10 min and followed by a maintenance infusion of \$.5 \mu g/kg/h until the last suture was applied, while the other study administrated dexmedetomidine as a maintenance infusion of 0.5 μg/kg/h antravenously after the induction of anaesthesia until 20 min before the surgery was finished. There was no significant difference in the dexmedetomidine group as compared to the placebo group. The haemodynamic stability was due to the method of low dose, slow injection and continuous infusion.

Few studies have focused on the effect of dexmedetomidine on PONV. Dexmedetomidine did not affect the incidence of PONV in our metaanalysis. This was consistent with a recent systematic review<sup>29</sup> in which dexmedetomidine intraoperative adm<sup>20</sup> istration had no effect upon PONV during paediatric surgery, but it was inconsistent with a recent systematic review<sup>30</sup> in which dexmedetomidine was superior to placebo with a reduction in the need for an antiemetic in adults undergoing gynaecological surgery. Another study also showed that dexmedetomidine appeared to prevent postoperative vomiting after sevoflurane anaesthesia for paediatric strabismus surgery. In their opinion, it is difficult to estimate the true incidence of nausea in younger children.<sup>31</sup> This may be the explanation for the different effects of dexmedetemidine on PONV between children and adults.

#### Limitations

There were still some limitations in our meta-analysis. First, only one study was designed with a low risk obbias, and the others had a moderate risk of bias. Second, due to differences in the doses and timing of administration, we did not use subgroup aralysis for the administration doses.

CONCLUSIONS

Conclusions

Our findings demonstrate that perioperative administration of dexmedetomidine in children undergoing CLP repair efficiently decreases pain, EA,

and respiratory adverse events. However, standardized usage and dosage need further investigation, and larger gigorous studies need to be included.

Author Contributions

LP, YG and XL helped read and screen abstracts and titles of potentially relevant studies. JL, FL and XL helped read the retained papers and were responsible for extracting data and assessing their quality independently. DL helped design the study, conduct the study, analyse the data, and write the manuscript. JQ helped revise the paper with language. CH and CL helped design the study, conduct t\overline{R}e study, analyse the data, and revise the manuscript. All authors contributed to conceptualize ideas, interpret findings and reviewed drafts of the manuscript.

Funding This work was supported by scientific research foundation of Wenzhou city in China grant number [Y2020592].

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited,

#### REFERENCES

- 1. Somerville N, Fenlon S. Anaesthesia for cleft lip and palate surgery. Contin Educ Anaesth Crit Care Pain 2005; 5: 76-9.
- 2. Takemura H, Yasumoto K, Toi T, Hosoyamada A. Correlation of cleft type with incidence of perioperative respiratory complications in infants with cleft lip and palate. Paediatr Anaesth 2002; 12: 585-8.
- 3. Tremlett M. Anaesthesia for cleft lip and palate surgery. Curr Anaesth Crit Care 2004; 15: 309-16.
- 4. Dahmani S, Stany I, Brasher C, et al. Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a metaanalysis of published studies. Br J Anaesth 2010; 104: 216-23.
- 5. Nguyen C, Davies SM, Curtin CM, et al. Cleft palate surgery: An evaluation of length of stay, complications and costs by hospital type. Cleft Palate Craniofac J 2014; 51: 412-9.
- 6. Lin TF, Yeh YC, Lin FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth 2009: 102: 117-22.
- 7.Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. Expert Opin DrugSaf 2011; 10: 55-66.
- 8. Sottas C E, Anderson B J. Dexmedetomidine: the new all-in-one drug in paediatric anaesthesia? Current opinion in anaesthesiology 2017, 30(4):441.
- 9.Cho H K, Yoon H Y, Jin H J, et al. Efficacy of dexmedetomidine for perioperative morbidities in pediatric consillectomy: A meta-analysis. *The* Laryngoscope 2017;128: E184-93.
- 10. Jun J H, Kim K N, Kim J Y, et al. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. ed by copyright Canadian Anaesthetists Society Journal 2017;64:947-61.

- 11. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (pdated march 2016). The Cochrane Collaboration, 2016. http:// handbook. cochrane. org/
- 12. Mostafa MF, Aal FAA, Herdan R, et al. Dexmedetomidine during suprazygomatic maxillary nerve block for pediatric cleft palate repair, randomized double-blind controlled study. *The Korean journal of pain* 2020; 33:81-9.
- 13. El-Emam EM, El Motlb EAA. Comparative Evaluation of Dexamethasone and Dexmedetomidine as Adju∮ants for Bupivacaine in Ultrasound-Guided Infraorbital Nerve Block for Cleft Lip Repair: A Prospective, Randomized, Double-Blind Study, Anesthesia, essays and researches 2019;13:354-8.
- 14. Obayah GM, Refaie A, Abdelazees M, et al. Addition of dexmedetomidine to bupivacaine for greater palatine nerve block prolongs postoperative analgesia after cleft palate repair. Eur J Anaesthesiol 2010; 27:280-4.
- 15. Peng W, Zhang T. Dexmedetomidine decreases the emergence agitation in infant patients undergoing cleft palate repair surgery after general anesthesia. BMC Anesthesiol 2015; 15:145-51.
- 16. Boku A, Hanamoto H, Niwa H, et al. Effectiveness of dexmedetomidine for emergence agitation in infants undergoing palatoplasty: a randomized controlled trial. Brazilian journal of anesthesiology 2016; 66:37-43.
- 17, Surana P, Parikh DA, Patkar GA, Tendolkar BA. A prospective randomized controlled double-baind trial to assess the effects of dexmedetomidine during cleft palate surgery. Korean J Anesthesiol 2017; 70:633-41.
- 18. Luo K, Xu JM, Cao L, Gao J. Effect of dexmedetomidine combined with sufentanil on preventing emergence agitation in children receiving otected by copyright sevoflurane anesthesia for cleft palate repair surgery. Exp Ther Med 2017; 14:1775-82.

- 19. Mei D, Cong H, Jun L, et al. Effect of single-dose dexmedetomidine on recovery period after sevorurane anesthesia with spontaneous respiration in pediatric patients undergoing cleft lip and palate repair. Zhonghua Yi Xue Za Zhi. 2014; 94:146 9-9. [Article in Chinese]
- 20. Xiao L, Long C, Jun F, Wen Z. Comparison of dexmedetomidine, ketamine and fentanyl in children undergoing cleft lip and palate surgery. *Zhejiang Practical Medicine* 2012; 17:173-5. [Article in Chinese]
- 21. Xi H, Zu H, Shou S, et al. The effect of recovery quality of dexmedetomidine for cleft lip and palate repair in children. Guangdong Medical Journal 2012; 33:2490-2. [Article in Chinese]
- 22. Yun L, Zhen L, Xu Y. Effects of intranasal dexmedetomidine for children undergoing cleft lip and palate epair surgery. *International Journal* of Stomatology 2016; 43:401-5. [Article in Chinese]
- 23. Ju P, Cheng Y, Ya J, Wan H. Efficacy of dexmedetomidine on recovery period in infants undergoing cleft lip and palate repair. Guangdong Medical Journal 2013; 34:1439-41. [Article in Chinese]
- 24. Jun P, Jun L, Jie L. Efficacy of dexmedetomidine on emergence agitation during recovery time in childen after cleft lip and palate surgery. *Zhejiang Traumatic Journal* 2018; 23:1250-1. [Article in Chinese]
- 25. Gerresheim G, Schwemmer U. Dexmedetomidine. Anaesthesist 2013; 62: 661–74.
- 26. Tan D, Xia H, Sun S, et al. Effect of ancillary drugs on sevoflurane related emergence agitation in children undergoing ophthalmic surgery: a Bayesian network meta-analysis. *BMC Anesthesiol* 2019,19:138-49.
- 27. Ni J, Wei J, Yao Y, et al. Effect of dexmedetomidine on preventing postoperative agitation in children:  $\frac{\ddot{\alpha}}{8}$  meta-analysis. *PLoS One* 2015,10: otected by copyright e0128450.

- 28. Sun L, Guo R. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: A mega-analysis of randomized controlled trials. *Acta Anaesthesiol Scand* 2014; 58:642-50.

  29. Bellon M, Le Bot A, Michelet D, et al. Efficacy of intraoperative dexmedetomidine compared with placebox for postoperative pain management:
- 29. Bellon M, Le Bot A, Michelet D, et al. Efficacy of intraoperative dexmedetomidine compared with placebox for postoperative pain management a meta-analysis of published studies. *Pain Ther* 2016; 5:63–80.
- 30. Liang X, Zhou M, Feng JJ, et al. Efficacy of dexmedetomidine on postoperative nausea and vomiting: a mesa-analysis of randomized controlled trials. *Int J Clin Exp Med* 2015; 8: 12113-34.
- 31.CHEN J Y, JIA J E, LIU T J, et al. Comparison of the effects of dexmedetomidine, ketamine, and pacebo on emergence agitation after strabismus surgery in children. *Can J Anaesth* 2013,60: 385-92.

### Figure captions:

Figure 1: Flow diagram of the literature search strategy

Figure 2: Risk of bias of the included studies.

Figure 3: Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidenc interval; RR: risk ratio.

Table 1 Characteristic	s of the included	randomized_	controlled trials
Table i Characteristic	s of the included	Tandomized-	controlled trials

Гable1 Char	acteristics o	f the included	l randomized-co	BMJ C	)pen	/bmjopen-2020-046798 on 1	
Study (year)	Country	Language	Age (month/year)	Other anesthetic agents	Administration method	Comparis En	Outcomes
Mostafa 2020 <sup>12</sup>	Egypt	English	1-5y	Sevoflurane, fentanyl, propofol	perineural	Dex(n=15\(\frac{1}{2}\)0.5\(\text{ug/kg}\) Control(n=15): saline	the incidence of need for rescue analgesia
El-Emam 2019 <sup>13</sup>	Egypt	English	3-6m	Sevoflurane, fentanyl, rocuronium	perineural	Dex(n=50 0.5 ug/kg Control(n=50): 0.1 mg/kg DA	the incidence of PONV
Obayah 2010 <sup>14</sup>	Egypt	English	11.7±2.4m 12±2.7m	Sevoflurane	perineural	Dex(n=15) lug/kg Control(n=15): saline	the incidence of PONV, need for rescue analgesia
Peng 2015 <sup>15</sup>	China	English	3-24m	Sevoflurane, fentanyl, propofol, cisatracurium, remifentanil	intravenous	Dex(n=20 0.8 ug/kg/min (continuous intravenous infusion after duction) Control(n=20): saline	the incidence of EA, PONV, airway spasm
Boku 2015 <sup>16</sup>	Japan	English	10-14m	Sevoflurane, fentanyl, rocuronium	intravenous	Dex(n=35)6ug/kg/h (10 min before the end of the surgery for 10 min) 2 +0.4ug/kg/h (continuous intravenous infusion until 5 5min before	the incidence of desaturation

				ВМЈ	Open	/bmjope	
						/bmjopen-2020-046798	
						extubate)	
						Control(n=35): saline	
Surana 2017 <sup>17</sup>	India	English	6m-12y	Sevoflurane, fentanyl, glycopyrrolate,	intravenous	Dex(n=30 1ug/kg+0.5ug/kg/h(sontinuous) intravenous infusion)	the incidence of need for rescue analgesia,
				vecuronium,		Control(n=30): 0.05 mg/kg	PONV,
				isoflurane		midazolan saline(continu	desaturation,
				isoliaiaiic		ous intravenous infusion)	hypotension,
						e e e e e e e e e e e e e e e e e e e	bradycardia
Luo	China	English	1-5y	Sevoflurane,	intravenous	Dex(n=50 0.5ug/kg (prior	the incidence of
$2017^{18}$				remifentanil		to indection of	EA, need for
						anesthesia)	rescue
						Control( $n = 0$ ): saline	analgesia,
						n. bn	PONV,
						nj. CC	breath-holding,
						bmj.com/ o	postoperative bleeding
Mei	China	Chinese	8m-3y	Sevoflurane,	intravenous	Dex(n=30≹0.5ug/kg	the incidence of
2014 <sup>19</sup>	Cilila	Cililicse	om by	morphine	muavenous	(30mm before	EA, PONV,
2011				шогрише		surgersy finish for	breath-holding,
						10min)	cough,
						Control(n ≥ 30): saline	desaturation,
						es	airway spasm
Xiao	China	Chinese	1.22±0.22y	Sevoflurane,	intravenous	Dex(n=18) 2ug/kg (during	the incidence of
$2012^{20}$			1.26±0.24y	vecuronium,		inducation)	EA, PONV,
			1.25±0.23y	propofol,		+0.5ug/kg/h	desaturation
			-				

						5798	
						(contgnuous	
						intravenous infusion	
						after attubation)	
						Control 1(=18):2mg/kg	
						(during induction)	
						$+0.5 \frac{\text{mg}}{\text{kg/h}}$	
						(cont <u>u</u> nous	
						intravenous infusion	
						after futubation)	
						ketangine	
						Control 2(=18):3ug/kg	
						(during induction) +	
						1ug/kæg (intermittent	
						administration twice)	
						fentağyl	
Xi	China	Chinese	1-3y	Sevoflurane,	intravenous	$Dex(n=15 \frac{8}{2} lug/kg (30min)$	
$2012^{21}$				midazolam		J & 3	EA,
				propofol,			breath-holding,
				cisatracurium,		Control( $n = 5$ ): saline	desaturation,
				fentanyl			airway spasm
Yun	China	Chinese	6m-3y	Sevoflurane,	intranasal		the incidence of
$2016^{22}$				propofol,			EA
				succinylcholine		Control(n=60): saline	
Ju	China	Chinese	4m-3y	Propofol,	intravenous	Dex(n=40) 0.5 ug/kg	the incidence of
$2013^{23}$				cisatracurium,		` <u>u</u>	EA, need for
				fentanyl		start <b>B</b> r 10min)	rescue
						by cc	

Table 2 Individual Randomized Controlled Trial Methodological Quality.

Гable 2 Individual	Randomized	Controlled Trial	l Methodological	BMJ Open Quality.		/bmjopen-2020-046798 on 16	
Study (year)	Adequate	Allocation	Blinding of	Blinding of	Incomplete	Fre of selective	Free of other
	sequence generation	concealment	Participants and Personnel	Outcome Assessment	outcome data addressed	repring	bias
Mostafa2020 <sup>12</sup>	yes	?	yes	yes	yes	yewsloadestroon http://www.brog.com/yewsloadestroon http://www.brog.com/yewsloadestroon/yewslo	yes
El-Emam2019 <sup>13</sup>	yes	yes	No	yes	yes	Nog	yes
Obayah2010 <sup>14</sup>	?	yes	No	No	yes	ye <u>ş</u>	yes
Peng2015 <sup>15</sup>	yes	yes	No	No	No	No∰	yes
Boku2015 <sup>16</sup>	yes	?	yes	yes	yes	? ∰	yes
Surana2017 <sup>17</sup>	yes	yes	yes	yes	yes	yes	yes
Luo2017 <sup>18</sup>	yes	?	yes	yes	yes	ye <u>s</u>	No
Mei2014 <sup>19</sup>	yes	?	No	No	yes	ye <b>ş</b>	yes
Xiao2012 <sup>20</sup>	No	?	No	No	yes	ye <mark>s</mark> .	yes
Xi2012 <sup>21</sup>	?	?	No	No	yes	Nog	yes
Yun2016 <sup>22</sup>	yes	?	yes	No	yes	yes	yes
$Ju2013^{23}$	?	?	No	No	yes	yes Noi Noi	yes
Jun2018 <sup>24</sup>	yes	?	No	No	yes	No∰	yes

Yes=low risk of bias; No=high risk of bias; ?=unclear risk of bias.

#### Dexmedetomidine for cleft lip and palate repair

		ВМЈ Ор	oen	<u>:</u>	/bmiopen-2020-046798 on 16	
Table 3 Summary of findings for th	e main outcomes			C	Aua	
Dexmedetomidine for cleft lip and palate repair					ust 2021.	
Patient or population: patients with cleft lip and pa	late repair				27.	
Settings: surgery					Oowr	
Intervention: Dexmedetomidine					Downloaded	
Outcomes	Illustrative compa	rative risks* (95% CI)	Relative effect		Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Control	Dexmedetomidine			(b) 	
Emergence agitation	Study population		RR 0.19	684		
	458 per 1000	87 per 1000	(0.10 to 0.36)	(8 studies)	© ⊕ ⊕ ⊖ ⊖ low <sup>1,2,3,4,5</sup>	
		(46 to 165)	0,_		<u>n.</u>	
Respiratory adverse events	<b>Study population</b>		RR 0.49	794		
	103 per 1000	50 per 1000	(0.31 to 0.78)	(8 studies)	⊕ ⊕ ⊕ ⊖ moderate <sup>1,6</sup>	
		(32 to 80)		<u> </u>	<u> </u>	
The need for postoperative rescue analgesics	Study population		RR 0.27			
	592 per 1000	160 per 1000	(0.1 to 0.73)	(5 studies)	00 ⊕ ⊕ ⊕ ⊕ moderate <sup>1,2,6</sup> by QC	
		(59 to 432)		(	0 0 0	
Cardiovascular adverse events	Study population		RR 0.83	880	est. ⊕ ⊕ ⊕ ⊝	
	105 per 1000	87 per 1000	(0.52 to 1.31)	(3 studies)	D moderate <sup>1</sup> tect	
		(55 to 138)			Hec.	

				9	92	
Postoperative Nausea and vomiting	Study population		RR 0.92			$\oplus \oplus \ominus \ominus$
	63 per 1000	58 per 1000	(0.47 to 1.80)		16 A	$\mathbf{low}^{\scriptscriptstyle 1}$
		(30 to 113)		,	ugus	
					t	

<sup>\*</sup>The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence in easumed risk in the comparison

nloaded from http://t

il 18, 2024 by guest. Protected by copyright

group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>&</sup>lt;sup>1</sup> Allocation concealment and/or blinding of outcome assessors unclear/inadequate in 50% or more of the included studies


<sup>&</sup>lt;sup>2</sup> Significant heterogeneity (I 2 > 50%) is partially explained by different administration method, dose and comparators.

<sup>&</sup>lt;sup>3</sup> Use of several different scoring criterias to evaluate emergence agitation.


<sup>&</sup>lt;sup>4</sup> a dose response gradient was present

<sup>&</sup>lt;sup>5</sup> RR >5 or <0.2

<sup>6</sup> RR >2 or <0.5




Flow diagram of the literature search strategy  $82x73mm (300 \times 300 DPI)$ 



Risk of bias of the included studies.

210x86mm (300 x 300 DPI)



Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidence interval; RR: risk ratio.

205x114mm (300 x 300 DPI)

**#1** dexmedetomidine [MeSH Terms]

#2 "cleft palate"[All Fields] OR "lip palate"[All Fields] OR "cleft palate and lip"[All Fields]

#3 infant or children or pediatric patient [All Fields]

#4 randomized controlled trial [All Fields]

#5 #1 and #2 and #3 and #4



# Risk of bias

# Mostafa2020<sup>12</sup> (ClinicalTrials.gov ID: NCT03412474).

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated program of random numbers
Allocation concealment (selection bias)	unclear	Not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Neither the doctors (investigators) nor the patients' guardians or even the children themselves were aware of the group allocation and the drug received. One anesthesiologist not involved in the block implementation or the data collection, prepared all the study solutions.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	While a third, blinded to the previous protocol, was responsible only for data collection.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 80 patients
Other bias	Low risk	Groups well balanced

# El-Emam2019<sup>13</sup> Clinical Trials.gov (NCT03480607)

1 2 3 4	El-Emam2019 <sup>13</sup> Clinical	Trials.gov ( <u>NC</u>	T03480607)
5 6 7 8	Bias	Authors' judgement	Support for judgement
9 10 11 12	Random sequence generation (selection bias)	Low risk	computer-generated randomization numbers
13 14	Allocation concealment (selection bias)	Low risk	a closed-seal envelope
15 16 17 18 19 20	Blinding of participants and personnel (performance bias) All outcomes	High risk	The principal investigator prepared the drug and performed the block
21 22 23 24 25	Blinding of outcome assessment (detection bias) All outcomes	Low risk	the person observing and recording the parameters was blinded to the study.
26 27 28 29	Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
30 31 32 33 34 35 36	Selective reporting (reporting bias)	High risk	The primary outcome was to compare both groups regarding time to first rescue analgesic, while the primary outcomes in the pre-registration site were postoperative FLACC scale and
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Other bias	Low risk	postoperative sedation score.  Groups well balanced
	For peer review o	only - http://bmjopo	en.bmj.com/site/about/guidelines.xhtml

# Obayah2010<sup>14</sup>

	Г	
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Unclear risk	"randomly allocated", no details
generation (selection		•
bias)		
Allocation concealment	Low risk	The randomization was achieved by the
(selection bias)		opening of a sealed envelope by the
		attending physician
Blinding of participants	High risk	Not mentioned
and personnel		
(performance bias)		
All outcomes	4	
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 30 patients
Other bias	Low risk	Groups well balanced
	1	

Peng2015<sup>15</sup> Chinese Clinical Trial Register (ChiCTR-TRC-13003865).

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly divided with a computer- generated sequence of numbers
Allocation concealment (selection bias)	Low risk	a sealed envelop
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	High risk	The actual sample was 40 while the planned sample in the pre-registration site was 60.
Selective reporting (reporting bias)	High risk	The primary outcome was to compare both groups regarding emergence agitation and time about recovery parameters while the primary outcomes in the pre-registration site were heart rate and blood pressure.
Other bias	Low risk	Groups well balanced

# **Boku2015**<sup>16</sup> (UMIN 000009869) http://upload.umin.ac.jp.

D:	A .1 1	
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	A computer-generated
generation (selection		random number table
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	Low risk	The patient's parents and the attending
and personnel		anesthesiologist were blinded to the group
(performance bias)		allocation
All outcomes	4	
Blinding of outcome	Low risk	Data for each patient were
assessment (detection		obtained by
bias)		the blinded anesthesiologist.
All outcomes		Ŭ l
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Unclear risk	Do not get the protocol
(reporting bias)		4.
Other bias	Low risk	Groups well balanced
		4

# Surana2017<sup>17</sup>

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	a computer-generated randomized chart
Allocation concealment (selection bias)	Low risk	The random group assignments were enclosed in a sealed opaque envelope
Blinding of participants and personnel (performance bias) All outcomes	Low risk	the surgeons, the patients, and the anesthesiologist in the post-anesthesia care unit (PACU) were all blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Data was recorded by a blinded observer.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 60 patients
Other bias	Low risk	Groups well balanced

# $Luo 2017^{18}$

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	a computer-generated table of
generation (selection		random numbers
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	Low risk	All pharmacological agents used in the
and personnel		present study were prepared and
(performance bias)		administrated by the anesthesiologists who
All outcomes		were blinded to the details of the study.
Blinding of outcome	Low risk	Pediatric Anesthesia Emergence Delirium
assessment (detection		and CHIPPS scores were documented by a
bias)		well-trained PACU nurse who was blinded
All outcomes		to the study.
Incomplete outcome	Low risk	4 patients from group DS and 3 patients
data (attrition bias)		from group SF were excluded from the
All outcomes		analysis
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 93 patients
		6
Other bias	High risk	Groups well balanced. Not in intention-to-
		treat: Of the 100 patients admitted to the
		study, 7 were later excluded by the authors
		for the reasons listed in table II, leaving data
		from 93 patients for consideration

# Mei2014<sup>19</sup>

generation (selection bias)  Allocation concealment (selection bias)  Blinding of participants and personnel (performance bias)  All outcomes  Blinding of outcome assessment (detection bias)  All outcomes  Incomplete outcome Low risk	ot mentioned.  ot mentioned.  ot mentioned.
(selection bias)  Blinding of participants High risk Nand personnel (performance bias)  All outcomes  Blinding of outcome assessment (detection bias)  All outcomes  Incomplete outcome Low risk Nand Nand Nand Nand Nand Nand Nand Nand	ot mentioned.
Blinding of participants and personnel (performance bias) All outcomes Blinding of outcome assessment (detection bias) All outcomes Incomplete outcome Low risk	
assessment (detection bias)  All outcomes  Incomplete outcome Low risk N	ot mentioned.
data (attrition bias) All outcomes	o loss to follow-up.
	ne authors provided results for all easurements for 60 patients
Other bias Low risk G	roups well balanced.

### Xiao2012<sup>20</sup>

	T	
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Lligh right	randamizad according to the according
'	High risk	randomized according to the operation
generation (selection		time sequence
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)		
All outcomes		
	<b>○</b> 1.15 - 1 - 2 - 1	Network
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 54 patients
( -		
Other bias	Low risk	Groups well balanced.

# $Xi2012^{21}$

	Γ	Γ
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Unclear risk	Random mentioned, no detail
generation (selection	21.0.00. 11010	
bias)		
Allocation concealment	Unclear risk	Not mentioned.
	Unclear risk	Not mentioned.
(selection bias)	110 - 1 - 2 -1	Network
Blinding of participants	High risk	Not mentioned.
and personnel		
(performance bias)		
All outcomes	<b>4</b>	
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up.
data (attrition bias)		
All outcomes		
Selective reporting	High risk	Lack of complications, such as
(reporting bias)		postoperative hoarseness, nausea and
		vomiting
Other bias	Low risk	Groups well balanced.
	<u> </u>	4

#### Yun2016<sup>22</sup>

		Authors' judgement	Support for judgement
Allocation concealment (selection bias)  Blinding of participants and personnel (performance bias)  All outcomes  Blinding of outcome assessment (detection bias)  All outcomes  Incomplete outcome data (attrition bias)  All outcomes  Selective reporting (reporting bias)  Mot mentioned.  Not mentioned.  Not mentioned.  Not mentioned.  Not mentioned.  Not mentioned.  The authors provided results for all measurements for 120 patients	generation (selection	Low risk	a table of random numbers, no detail
and personnel (performance bias) All outcomes  Blinding of outcome assessment (detection bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting Low risk (reporting bias)  All outcomes  The authors provided results for all measurements for 120 patients	Allocation concealment	Unclear risk	Not mentioned.
assessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (reporting bias)  The authors provided results for all measurements for 120 patients	and personnel (performance bias)	Low risk	
data (attrition bias) All outcomes Selective reporting Low risk The authors provided results for all measurements for 120 patients	assessment (detection bias)	High risk	Not mentioned.
(reporting bias) measurements for 120 patients	data (attrition bias)	Low risk	No loss to follow-up.
Other bias Low risk Groups well balanced.	' 0	Low risk	
	Other bias	Low risk	Groups well balanced.

#### $Ju2013^{23}$

6.					
Bias	Authors'	Support for judgement			
	judgement				
Random sequence	Unclear risk	Mentioned random, no detail			
generation (selection					
bias)					
Allocation concealment	Unclear risk	Not mentioned.			
(selection bias)					
Blinding of participants	High risk	Not mentioned.			
and personnel					
(performance bias)					
All outcomes	4				
Blinding of outcome	High risk	Not mentioned.			
assessment (detection					
bias)					
All outcomes					
Incomplete outcome	Low risk	No loss to follow-up.			
data (attrition bias)					
All outcomes					
Selective reporting	Low risk	The authors provided results for all			
(reporting bias)		measurements for 80 patients			
Other bias	Low risk	Groups well balanced.			
		4			

#### Jun2018<sup>24</sup>

4 5	Jun2018 <sup>24</sup>		
6 7 8 9	Bias	Authors' judgement	Support for judgement
10 11 12 13	Random sequence generation (selection bias)	Low risk	Compute randomized
14 15 16	Allocation concealment (selection bias)	Unclear risk	Not mentioned.
17 18 19 20 21	Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned.
22 23 24 25 26	Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
27 28 29 30	Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
31 32 33 34 35	Selective reporting (reporting bias)	High risk	The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.
36 37	Other bias	Low risk	Groups well balanced.
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60			
	For peer review o	only - nttp://bmJope	en.bmj.com/site/about/guidelines.xhtml




Figure 1 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.1 emergence agitation.




Figure 2 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.2 postoperative nausea and vomiting.




Figure 3 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.3 complication in respiration.




Figure 4 Funnel plot of comparison: dexmedetomidine vs control, outcome: 1.4 complication in circulation.




Figure 5 Funnel plot of comparison: dexmedetomidine vs control, outcome:1.5 postoperative analgesia rescue.



### PRISMA 2009 Checklist

Section/topic	#	Checklist item 679	Reported on page #
TITLE		n 16	1-2
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1-2
ABSTRACT		lst 2	3-4
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION		lo ad	5
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS		//bm	6-8
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study guthors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g.el²) for each metatanalysis pen.bmj.com/site/about/guidelines.xhtml	6-7



38 39

45 46

#### PRISMA 2009 Checklist

		BMJ Open	Page 52 of 5
PRISMA 20	09	Checklist -2020	
i		Page 1 of 2	
Section/topic	#	Checklist item 798 on 1	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS		Do	8-12,21-27
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
7 Study characteristics 8	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9,21-24
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9,25
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9,10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9-10,26-27
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION		A P	12-15
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
2 Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., ingomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14,15
FUNDING		Prot	15
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data; role of funders for the systematic review.	15

41
42 From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

# **BMJ Open**

## Efficacious of dexmedetomidine in children undergoing cleft lip and palate repair: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-046798.R2
Article Type:	Original research
Date Submitted by the Author:	30-Jun-2021
Complete List of Authors:	Liu, Dengfeng; Wenzhou Medical University School of Stomatology-Affiliated Stomatological Hospital, Department of Oral Maxillofacial Surgery Pan, Li; Wenzhou Medical University School of Stomatology-Affiliated Stomatological Hospital, Department of Oral Maxillofacial Surgery Gao, Yin; Wenzhou Medical University School of Stomatology-Affiliated Stomatological Hospital, Department of Oral Maxillofacial Surgery Liu, Jiefan; Wenzhou Medical University School of Stomatology-Affiliated Stomatological Hospital, Department of Oral Maxillofacial Surgery Li, Feng; Wenzhou Medical University School of Stomatology-Affiliated Stomatological Hospital, Department of Oral Maxillofacial Surgery Li, Xiangwei; people's liberation army air force health care center for special service, Department of Rehabilitation Quan, Jiale; Wenzhou Medical University Second Affiliated Hospital, Department of Anesthesiology and Perioperative Medicine HUANG, CONGCONG; Wenzhou Medical College Second Affiliated Hospital, Department of Anesthesiology and Perioperative Medicine Lian, Chunwei; Wenzhou Medical College Second Affiliated Hospital, Department of Anesthesiology and Perioperative Medicine
<b>Primary Subject Heading</b> :	Surgery
Secondary Subject Heading:	Anaesthesia, Paediatrics, Dentistry and oral medicine
Keywords:	ORAL & MAXILLOFACIAL SURGERY, Paediatric anaesthesia < ANAESTHETICS, Pain management < ANAESTHETICS

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Efficacious of dexmedetomidine in children undergoing cleft lip and palate repair: a systematic reviewand meta-analysis

Dengfeng Liu<sup>1</sup>, Li Pan<sup>1</sup>, Yin Gao<sup>1</sup>, Jiefan Liu<sup>1</sup>, Feng Li<sup>1</sup>, Xiangwei Li<sup>3</sup>, Jiale Quan<sup>2</sup>,

Congcong Huang<sup>2\*</sup>, Chunwei Lian<sup>2\*\*</sup>

- 1.Department of Oral Maxillofacial Surgery, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
- 2.Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical

University; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.

3. Department of Rehabilitation, Air Force Health Care Center For Special Service Hangzhou, Hangzhou, Zhejiang, P.R. China.

\*The Co-corresponding author: Dr. Congcong Huang Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou 325027, China.

E-mail: congconghuang2009@163.com

Tel: +86-13676757360

\*\*The Co-corresponding author: Dr. Chunwei Lian

Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou 325027, China. E-mail: lianchunwei0203@163.com Tel: +86-13868702680 

BMJ Open

oy copyright

#### **ABSTRACT**

Objective To systematically assess the efficacy and safety of dexmedetomidine as an anaesthesia adjuvant for cleft lip and palate (CLP) repair in children.

**Design** Systematic review and meta-analysis.

Data sources PubMed, Embase, Cochrane, CNKI, VIP, and Wanfang (up to Oct 2020). Studies in languages ther than English and Chinese were excluded.

Eligibility criteria for selecting studies Randomized controlled trials (RCTs) evaluating the impact of dexmedetomidine on emergence agitation (EA), the need for postoperative rescue analgesics, postoperative nausea and vomiting (PONV), and other deverse events in paediatric patients during CLP repair.

Data extraction and synthesis The quality of evidence was assessed by using the Cochrane Review Methods and the Grading of Recommendations Assessment, Development, and Evaluation approach. Data were screened, extracted and assessed by two independent authors.

Outcomes were reported as a risk ratio (RR) with a 95% confidence interval (CI). A random effect mode was used when heterogeneity was detected.

Results Thirteen studies including 1040 children met the inclusion criteria. The incidence of EA was significantly decreased in the dexmedetomidine group (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I<sup>2</sup>=56%) as compared to the control group. Paediatric patients receiving dexmedetomidine had lower postoperative analgesic requirements (RR, 0.27; 95% CI, 0.10 to 0.73; P=0.0 to 0.73

cardiovascular adverse events.

Conclusions There was a lack of high-quality studies in this field. Perioperative administration of dexidedetomidine reduced the need for postoperative rescue analgesics and the incidence of EA in children without side effects undergoing CLP repair. However, further verification with larger samples and higher quality RCTs are needed.

Keywords children, dexmedetomidine, cleft lip and palate repair, pain, emergence agitation

#### **ARTICLE SUMMARY**

#### Strengths and limitations of this study

Studies in both English language and Chinese language were included.

This is a comprehensive systematic review that identified the benefits of dexmedetomidine in children under coing CLP repair.

Heterogeneity was observed in the doses, the timing of administration and evaluation methods for the outconses across studies.

For some comparisons, the numbers of trials included and the outcomes reported were small.

The low quality of the included studies impedes us from drawing firm conclusions.

Word account: 4226

\_

#### **INTRODUCTION**

Cleft lip and palate (CLP) are widespread congenital disfigurements requiring surgical correction early in life. Early surgery is important to alleviate feeding difficulty, reduce airway complications and improve phonation problems. However, cleft  $\mathring{\mathbf{g}}$  alate repair is needed to dissect the soft and hard palates and may result in significant postoperative oropharyngeal pain and bleeding. High-dose opioids with sevoflurane anaesthesia are commonly used to block the autonomic response, while many paediatric patients suffer from high risks of spiratory depression, postoperative emergence agitation (EA), postoperative nausea and vomiting (PONV), prolonged hospital stay and increased hospital costs.<sup>4-6</sup>

Dexmedetomidine is a potent α2 adrenoreceptor agonist with sedative, anxiolytic, sympatholytic and analgesic properties. It alleviated the autonomic response to surgery and ensured a stable haemodynamic state without significant respiratory depression. One previous study had demonstrated that dexmedetomidine was helpful as a valuable adjunct for multiple applications and was increasingly used in paediatric anaesthesia settings. A meta-analysis recently showed that perioperative administration of dexmedetomidine can provide pain and agitation relief without side effects in children undergoing adenotonsillectomy. Another meta-analysis 10 found that intranasal dexmede omidine provided more satisfactory sedation at parent separation and reduced the need for postoperative rescue analgesics in paediatric patients. However, evidences in the existing literature were still insufficient to fully support the effective and safe use of dexmedetomidine in children undergoing CLP repair.

Therefore, our study aimed to identify the efficacy and safety of dexmedetomidine in children during CLP repair. We performed a meta-analysis by guest. Protected by copyright of randomized controlled trials comparing dexmedetomidine with controls.

#### **METHODS**

We evaluated the efficacy and safety of dexmedetomidine administration during CLP repair in children. A sestematic review approach based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and the Cochrane Review Method was used.  $^{11}$ 

#### Search strategy and selection criteria

We searched the following databases from inception to October 1, 2020: PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang. The main keywords used were: dexmedetomidine, randomized controlled trial (RCT), cleft palate, cleft lip, infan\( \beta \) and children. The reference lists of identified studies were searched for additional eligible studies. (search strategy of PubMed as supplementary lile1)

#### Inclusion and exclusion criteria

Two authors (LP and YG) systematically and independently identified all the studies using predefined selection criteria. A third author (XL) resolved disagreements when conflicting selections occurred. Studies were included in this meta-analysis it they met the following criteria: 1) Literature type: prospective, randomized controlled studies; 2) Language: both English and Chinese; 3) Subjects: children undergoing CLP repair; 4) Interventions: dexmedetomidine by any route of administration compared with any controls(including sagne and other drugs); 5) Outcomes: the primary outcome was the incidence of EA, the secondary outcome was the need for postoperative rescue analgesia, and the third outcomes were the incidence of adverse effects: PONV, respiratory adverse effects (breath-holding, cough, desaturation and airway spasm), and otected by copyright cardiovascular adverse effects (hypotension, bradycardia and postoperative bleeding).

#### **Data collection**

Two authors (JL and FL) independently extracted all the relevant information with a prespecified data abstraction form. The following variables were collected: the name of the first author, publication year, country, publication language, other anaesthetic gents, number of patients, protocol for administration method and dose, and outcomes. If the variables were not reported, we emailed the original authors to ask for the data.

#### Risk of bias across studies

Two authors (JL and FL) independently assessed the risk of bias based on the Cochrane risk of bias tool, which considers the following aspects: adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessor, incomplete reporting of outcome data, free of selective reporting, and free of other bias. We assessed the risk of bias based on the information presented in the studies, with no assumptions: low risk of bias, high risk of bias or unclear risk of bias. In case of conflicting valuations, a third author (XL) was consulted to resolve disagreements.

#### Quality of the evidence

The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE). We used GRADE profiler software version 3.2 to create the "Summary of findings" table, which includes the following outcomes: 1) EA; 2) respiratory adverse events; 3) the need for postoperative rescue analgesics; 4) cardiovascular adverse events; and 5) PONV.

/bmjopen-2020-046798 on 16 August 2021.

#### **Publication bias across studies**

Publication bias was assessed by using a funnel plot or Begg's test.

#### Statistical analysis

The meta-analysis was performed using Cochrane Collaboration Review Manager Software (RevMan version 5.1, https://training.cochrane.org/). We reported binary data as a risk ratio (RR) with a 95% confidence interval (CI). The chi-square test (Mantel Faenszel method) was used to assess the heterogeneity between studies. An  $I^2 > 50\%$  and a P-value < 0.10 were considered to indicate statistical feterogeneity. Subgroup analysis or sensitivity analysis was performed to analyze reasons for heterogeneity. A random effect model (DerSimonian and Laird method) was used when significant statistical or clinical heterogeneity was detected.  $P \le 0.05$  was considered to indicate a statistically significant difference for testing values of the overall effect.

#### Patient and public involvement

There was no patient or public involvement in this study.

#### **RESULTS**

#### **Study selection**

A total of 63 potentially relevant studies were identified. After excluding 50 studies, 13 studies including 104 children aged 3 months to 12 years

were finally included in this analysis. 12-24 The flow diagram of the literature search strategy is shown in Fig

#### **Description of studies**

The included studies were undertaken from 2012-2020 in four different countries: Egypt (three)<sup>12-14</sup>, Japan (one)<sup>16</sup>, India (one)<sup>17</sup>, and China (eight)<sup>15,18-24</sup>. Seven studies<sup>12-18</sup> were published in English, and the other six studies<sup>19-24</sup> were published in Clanese. In all of the included studies, dexmedetomidine was administered via intravenous 15-21,23,24, intranasal22 and perineural12-14 administration.

Eleven studies 12,14-19,21-24 compared the effects of intravenous dexmedetomidine with saline, and one study compared the effects of intravenous dexmedetomidine with those of ketamine and fentanyl. One study<sup>22</sup> compared the effects of intrapasal dexmedetomidine with saline. Two studies<sup>12,14</sup> compared the effects of perineural dexmedetomidine administration with saline, and one study<sup>3</sup> compared the effects of perineural dexmedetomidine administration with those of dexamethasone. The characteristics of the included studies ar summarized in Table 1.

#### Risk of bias across studies

The risk of bias of included studies can be found in Table 2, Fig 2 and Supplementary file 2. Nine studies 12 \$\frac{3}{5}\$,15-19,22,24 used a random allocation method. Four studies <sup>13-15,17</sup>described the allocation concealment in detail. Four studies <sup>12,16-18</sup> concretely explained their blinding methods. The risk of the random allocation method was high in one study<sup>20</sup> and was unclear in the other three studies<sup>14,21,23</sup>. The risk of allocation concealment was unclear and the risk of blinding was high in the other studies. The risk of free of selective reporting was lower eight studies 12,14,17-20,22,23, unclear in one study<sup>16</sup> and high in other studies. For incomplete outcome data and free of other bias, most trials were judged as having a low risk of bias. tected by copyright The quality of the included trials is summarized in Table 2, Fig 2 and supplementary file 2.

#### **Quality of the included studies**

The overall quality of evidence based on the GRADE system was judged as moderate (the need for postoperative rescue analgesics, respiratory adverse events, and cardiovascular adverse events), or low (EA and PONV) (Table 3).

#### **Publication bias across studies**

Test for funnel plot asymmetry was inappropriate to assess risk of publication bias. Since no significant as metry patterns were identified in Begg's test (supplementary file 3), we concluded no significant publication bias. Due to the small number of studies, the power is still low.

#### **Emergence agitation**

Eight trials<sup>15,18-24</sup> including 684 patients reported the incidence of EA. EA was evaluated by the Ramsay score, behaviour score, Pediatric Anesthesia Emergence Delirium scale, or Aonos four-point scale. Dexmedetomidine administration (including intravenous and intranasal administration) showed significant evidence of reduced EA when compared with saline<sup>15,18,19,21-24</sup> (RR, 0.19; 95% CI, 0.10 to 0.38; P<0.00001; I<sup>2</sup> = 62%) and all control groups<sup>15,18-24</sup> (RR, 0.19; 95% CI, 0.10 to 0.36; P<0.00001; I<sup>2</sup> = 56%). We found that different administration methods of dexmedetomidine increased the clinical heterogeneity. Excluding the 2016 study by Yun<sup>22</sup> (intradiasal administration), intravenous dexmedetomidine administration showed a significant evidence of reduced EA when compared with saline<sup>15</sup> (RR, 0.24;95% CI, 0.13 to 0.44; P<0.00001; I<sup>2</sup>=40%), and when compared with all control groups <sup>15,18-21,23,24</sup> (RR, 0.24;95% CI, 0.14 to (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19) and intravenous ketamine<sup>20</sup> (RR, 0.14; 95% CI, 0.01 to 2.58; P=0.19). (Fig 3).

#### The need for postoperative rescue analgesics

Five studies <sup>12,14,17,18,23</sup> including 293 paediatric patients reported that dexmedetomidine had a greater analgeone effect than saline postoperatively (RR, 0.27; 95% CI, 0.10 to 0.73; P=0.01; I<sup>2</sup>=84%). In contrast to the two studies that used perine administration <sup>12,14</sup>, intravenous dexmedetomidine administration <sup>17,18,23</sup> showed a significant analgesic effect when compared with saline (RR, 0.26; 95% CI, 0.16 to 0.44; P<0.00001; I<sup>2</sup>=0%). Subgroup analysis showed that there was no difference when perineural dexmedetomid are <sup>12,14</sup> was compared with saline in the incidence of need for rescue analgesics at postoperative 24 h (RR, 0.16; 95% CI, 0.00 to 33.36; P=0.50).

#### Respiratory adverse events

Eight studies<sup>15-21,23</sup> including 794 paediatric patients reported the number of respiratory adverse eigents. We found that intravenous dexmedetomidine administration showed a significantly lower incidence of respiratory adverse events than saline administration (RR, 0.49; 95% CI, 0.31 to 0.78; P=0.003; I<sup>2</sup>=0%). Only one study<sup>19</sup> (n=60) reported that dexmedetomidine showed a significantly lower incidence of cough than saline (RR, 0.45; 95% CI, 0.25 to 0.82; P=0.009). There were no differences when dexmedetomidine was compared with saline in the incidence of breath holding<sup>18,19,21</sup> (RR, 1.35; 95% CI, 0.31 to 5.92; P=0.69; I<sup>2</sup>=0%), desaturation<sup>16,17,19-21,23</sup> (RR, 0.47; 95% CI, 0.17 to 1.29; P=0.14; I<sup>2</sup>=0%) or airway spasm<sup>15,19,21</sup> (RR, 0.33; 95% CI, 0.07 to 1.54; P=0.16; I<sup>2</sup>=0%).

#### Cardiovascular adverse events

Three studies 17,18,24 including 880 paediatric patients reported the number of cardiovascular adverse events. We found that no differences when dexmedetomidine was compared with saline in the incidence of hypotension 17,24 (RR, 1.18; 95% CI, 0.61 to 2.28; P=0.62), bradycardia 17,24 (RR,

0.78; 95% CI, 0.30 to 2.07; P=0.62) or postoperative bleeding  $^{18,24}$  (RR, 0.45; 95% CI, 0.17 to 1.15; P=0.09; P=0.09).

#### Postoperative Nausea and vomiting

Eight trials<sup>13-15,17-20,23</sup> including 524 patients reported the incidence of PONV. Patients who received dexmede middle administration experienced no statistically significant increase in PONV when compared with saline <sup>14,15,17-19,23</sup> (RR, 0.95; 95% CI, 0.4 to 2.19; P=0.91; I<sup>2</sup>=0%), and when compared with all control groups<sup>13-15,17-20,23</sup> (RR, 0.96; 95% CI, 0.48 to 1.90; P=0.90; I<sup>2</sup>=0%). Subgroup analysis showed that there was also no difference when perineural dexmedetomidine was compared with control groups<sup>13,14</sup>. Additionally, another subgroup analysis showed no difference when intravenous dexmedetomidine was compared with fentanyl<sup>20</sup> (RR, 0.50; 95% CI, 0.06 to 4.15; P=0.52) and ketamine <sup>20</sup> (RR, 0.50; P=0.70).

#### **DISCUSSION**

#### **Main findings**

This meta-analysis revealed that perioperative administration of dexmedetomidine reduced the incidence of En in children undergoing CLP repair. Paediatric patients receiving dexmedetomidine had a lower need for rescue analgesics postoperatively and a lower incidence of respiratory adverse events. However, there were no significant differences in the risk of PONV and cardiovascular adverse events.

Although dexmedetomidine is not approved by U.S. Food and Drug Administration (FDA) for administration in children, it has been an authorized drug in Europe since September 2011.<sup>25</sup> It is increasingly used in the pediatric setting for various indications such as premedication,

ed by copyright

 adjunct, sedative, intraoperative analgesia, and adjuvant therapy<sup>8</sup>, but the efficacy is still controversial.

Our results found that both the incidence of EA and the need for rescue analgesics postoperatively were significantly decreased in the dexmedetomidine group as compared to the saline group. This was consistent with previous studies. 4,6,9,10 two recent meta-analyses<sup>26,27</sup> found that the effects of dexmedetomidine on reducing the risk of EA in children were superior to those of other drugs (including fentanyl, propofol, ketamine), which was inconsistent with our study. Numerous aetiological factors (such as pre-existing anxiety, pain, age, type of surgical procedures, rapid awakening and anaesthetic technique) were considered to cause EA.<sup>28</sup> All of the included studies used sevoflurane anaesthesia. It is widely believed that pain relief of decreases the incidence of EA associated with sevoflurane general anaesthesia. 9,28 Dexmedetomidine shows dose-dependent effects on pain control and sedation. Reliable analgesic, sedative and neuroprotective effects could be the main explanations for the effects of dexmedetomidine on EA.

Respiration is slightly affected by dexmedetomidine. Our meta-analysis showed that dexmedetomiding did not influence the incidence of breath-holding, desaturation or airway spasm. In contrast, the incidence of cough and total respiratory adverse events were decreased in the dexmedetomidine group. This was attributed to the residual sedation caused by the sedative effect of dexmedetomidine. Due to the rapid decrease in the concentration of sevoflurane during the recovery period, rapidly awakening paediatric patients were in a bighly sensitive state. It has minimal respiratory changes from the residual sedation, even extubation during the infusion of dexmedetomidine, in contrast to other sedatives. However, we should pay attention to the fact that the strength of residual sedation was related to the early phase of postanaesthesia recovery time in postoperative anaesthesia care unit.

As a selective α2-agonist, dexmedetomidine acts on the autonomic ganglia and exerts its cardiovascular effect by decreasing sympathetic outflow

/bmjopen-2020-046798

 and augmenting vagal activity, thus low infusion rates could cause bradycardia and hypotension while high doses could cause hypertension and aggravate bradycardia. In addition to the dose, rapid injection may result in excessive haemodynamic alterations, and it is recommended that dexmedetomidine be administered slowly. Only two of thirteen included studies reported the incidence of bradycardia and hypotension. One study administered dexmedetomidine as a loading dose over 10 min and followed by a maintenance infusion of  $0.5 \mu g/kg/h$  until the last suture was applied, while the other study administrated dexmedetomidine as a maintenance infusion of  $0.5 \mu g/kg/h$  intravenously after the induction of anaesthesia until 20 min before the surgery was finished. There was no significant difference in the dexmedetomidine group as compared to the placebo group. The haemodynamic stability was due to the method of low dose, slow injection and continuous infusion.

Few studies have focused on the effect of dexmedetomidine on PONV. Dexmedetomidine did not affect the incidence of PONV in our metaanalysis. This was consistent with a recent systematic review<sup>29</sup> in which dexmedetomidine intraoperative administration had no effect PONV
during paediatric surgery, but it was inconsistent with a recent systematic review<sup>30</sup> in which dexmedetomidine was superior to placebo with a
reduction in the need for an antiemetic in adults undergoing gynaecological surgery. Another study also showed that dexmedetomidine appeared
to prevent postoperative vomiting after sevoflurane anaesthesia for paediatric strabismus surgery. In their opingon, it is difficult to estimate the true
incidence of nausea in younger children.<sup>31</sup> This may be the explanation for the different effects of dexmedetomidine on PONV between children
and adults.

#### Limitations

There were some limitations in methodology. First, most of the studies were focused on developing countries, which might be relevant with that CLP disease was common in developing countries. But only one study was designed with a low risk of bias, and the others had a moderate risk of

bias. There are some possibilities of selective bias, detection bias, performance bias and so on. Second, due to differences in the doses and timing of administration, we did not use subgroup analysis for the administration doses. To a certain extent, it affected the strength of the system review.

#### **CONCLUSIONS**

Our findings demonstrate that perioperative administration of dexmedetomidine in children undergoing CLP pair efficiently decreases pain, EA, and respiratory adverse events. However, standardized usage and dosage need further investigation, and larger gigorous studies need to be included.

#### **Author Contributions**

LP, YG and XL helped read and screen abstracts and titles of potentially relevant studies. JL, FL and XL helped read the retained papers and were responsible for extracting data and assessing their quality independently. DL helped design the study, conduct the study, analyse the data, and write the manuscript. JQ helped revise the paper with language. CH and CL helped design the study, conduct the study, analyse the data, and revise the manuscript. All authors contributed to conceptualize ideas, interpret findings and reviewed drafts of the manuscript.

Funding This work was supported by scientific research foundation of Wenzhou city in China grant number [Y2020592].

Competing interests None declared.

Patient consent for publication Not required.

Page 17 of 50
BMJ Open

**Ethics approval** 

Ethics approval to collect the patients' data was not required by the Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and an indication of whether changes were made is provided. See: https:// creative commons. org/ licenses/ by/ 4.0

#### **ORCID iD**

Chunwei Lian: <a href="https://orcid.org/0000-0003-4702-6147">https://orcid.org/0000-0003-4702-6147</a>

Dengfeng Liu: https://orcid.org/0000-0001-9676-5996

/bmjopen-2020-046798 on 16 August 2021. Down

#### **REFERENCES**

- 1. Somerville N, Fenlon S. Anaesthesia for cleft lip and palate surgery. Contin Educ Anaesth Crit Care Pain 2005; 5: 76-9.
- 2. Takemura H, Yasumoto K, Toi T, Hosoyamada A. Correlation of cleft type with incidence of perioperative respiratory complications in infants with cleft lip and palate. *Paediatr Anaesth* 2002; 12: 585-8.
- 3. Tremlett M. Anaesthesia for cleft lip and palate surgery. Curr Anaesth Crit Care 2004; 15: 309-16.
- 4.Dahmani S, Stany I, Brasher C, et al. Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies. *Br J Anaesth* 2010; 104: 216-23.
- 5.Nguyen C, Davies SM, Curtin CM, et al. Cleft palate surgery: An evaluation of length of stay, complications and costs by hospital type. *Cleft Palate Craniofac J* 2014; 51: 412-9.
- 6. Lin TF, Yeh YC, Lin FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patients—controlled analgesia. *Br J Anaesth* 2009; 102: 117-22.
- 7.Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. *Expert Opin Drug* Saf 2011; 10: 55-66.
- 8. Sottas C E, Anderson B J. Dexmedetomidine: the new all-in-one drug in paediatric anaesthesia? Current opinion in anaesthesiology 2017, 30(4):441.

9.Cho H K, Yoon H Y, Jin H J, et al. Efficacy of dexmedetomidine for perioperative morbidities in pediatric onsillectomy: A meta-analysis. *The* Laryngoscope 2017;128: E184-93.

10. Jun J H, Kim K N, Kim J Y, et al. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. Canadian Anaesthetists Society Journal 2017;64:947-61.

- 11. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (special march 2016). The Cochrane Collaboration, 2016. http:// handbook. cochrane. org/
- 12. Mostafa MF, Aal FAA, Herdan R, et al. Dexmedetomidine during suprazygomatic maxillary nerve black for pediatric cleft palate repair, randomized double-blind controlled study. The Korean journal of pain 2020; 33:81-9.
- 13. El-Emam EM, El Motlb EAA. Comparative Evaluation of Dexamethasone and Dexmedetomidine as Adjugants for Bupivacaine in Ultrasound-Guided Infraorbital Nerve Block for Cleft Lip Repair: A Prospective, Randomized, Double-Blind Study. Anesthesia, essays and researches 2019;13:354-8.
- 14. Obayah GM, Refaie A, Abdelazees M, et al. Addition of dexmedetomidine to bupivacaine for greater palatine nerve block prolongs postoperative analgesia after cleft palate repair. Eur J Anaesthesiol 2010; 27:280-4.
- 15. Peng W, Zhang T. Dexmedetomidine decreases the emergence agitation in infant patients undergoing close palate repair surgery after general anesthesia. BMC Anesthesiol 2015; 15:145-51.
- 16. Boku A, Hanamoto H, Niwa H, et al. Effectiveness of dexmedetomidine for emergence agitation in infants undergoing palatoplasty: a otected by copyright randomized controlled trial. Brazilian journal of anesthesiology 2016; 66:37-43.

- 18. Luo K, Xu JM, Cao L, Gao J. Effect of dexmedetomidine combined with sufentanil on preventing emergence agitation in children receiving sevoflurane anesthesia for cleft palate repair surgery. *Exp Ther Med* 2017; 14:1775-82.
- 19. Mei D, Cong H, Jun L, et al. Effect of single-dose dexmedetomidine on recovery period after sevo urane anesthesia with spontaneous respiration in pediatric patients undergoing cleft lip and palate repair. *Zhonghua Yi Xue Za Zhi*. 2014; 94:1469-9. [Article in Chinese]
- 20. Xiao L, Long C, Jun F, Wen Z. Comparison of dexmedetomidine, ketamine and fentanyl in children undergoing cleft lip and palate surgery.

  Zhejiang Practical Medicine 2012; 17:173-5. [Article in Chinese]
- 21. Xi H, Zu H, Shou S, et al. The effect of recovery quality of dexmedetomidine for cleft lip and palate repair in children. *Guangdong Medical Journal* 2012; 33:2490-2. [Article in Chinese]
- 22. Yun L, Zhen L, Xu Y. Effects of intranasal dexmedetomidine for children undergoing cleft lip and palate pair surgery. *International Journal of Stomatology* 2016; 43:401-5. [Article in Chinese]
- 23. Ju P, Cheng Y, Ya J, Wan H. Efficacy of dexmedetomidine on recovery period in infants undergoing cleft lip and palate repair. *Guangdong Medical Journal* 2013; 34:1439-41. [Article in Chinese]
- 24. Jun P, Jun L, Jie L. Efficacy of dexmedetomidine on emergence agitation during recovery time in children after cleft lip and palate surgery.

  \*\*Zhejiang Traumatic Journal 2018; 23:1250-1. [Article in Chinese]
- 25. Gerresheim G, Schwemmer U. Dexmedetomidine. *Anaesthesist* 2013; 62: 661–74.

- 26. Tan D, Xia H, Sun S, et al. Effect of ancillary drugs on sevoflurane related emergence agitation in children undergoing ophthalmic surgery: a Bayesian network meta-analysis. *BMC Anesthesiol* 2019,19:138-49.
- Bayesian network meta-analysis. *BMC Anesthesiol* 2019,19:138-49.

  27. Ni J, Wei J, Yao Y, et al. Effect of dexmedetomidine on preventing postoperative agitation in children:

  e0128450.
- 28. Sun L, Guo R. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: A meta-analysis of randomized controlled trials. *Acta Anaesthesiol Scand* 2014; 58:642-50.
- 29. Bellon M, Le Bot A, Michelet D, et al. Efficacy of intraoperative dexmedetomidine compared with placebose postoperative pain management: a meta-analysis of published studies. *Pain Ther* 2016; 5:63–80.
- 30. Liang X, Zhou M, Feng JJ, et al. Efficacy of dexmedetomidine on postoperative nausea and vomiting: a mega-analysis of randomized controlled trials. *Int J Clin Exp Med* 2015; 8: 12113-34.
- 31.CHEN J Y, JIA J E, LIU T J, et al. Comparison of the effects of dexmedetomidine, ketamine, and pacebo on emergence agitation after strabismus surgery in children. *Can J Anaesth* 2013,60: 385-92.

#### Figure captions:

Figure 1: Flow diagram of the literature search strategy

Figure 2: Risk of bias of the included studies.

BMJ Open

BMJ Open

Figure 3: Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidence interval; RR: risk ratio.

Table1 Characteristics of the included randomized-controlled trials.

						oa ad	
Study (year)	Country	Language	Age (month/year)	Other anesthetic agents	Administration method	Comparis on Signature	Outcomes
Mostafa 2020 <sup>12</sup>	Egypt	English	1-5y	Sevoflurane, fentanyl, propofol	perineural	Dex(n=15,0.5ug/kg Control(n=5): saline	the incidence of need for rescue analgesia
El-Emam 2019 <sup>13</sup>	Egypt	English	3-6m	Sevoflurane, fentanyl, rocuronium	perineural	Dex(n= $50^{\circ}$ 0.5ug/kg Control(n= $50$ ): 0.1mg/kg DA	the incidence of PONV
Obayah 2010 <sup>14</sup>	Egypt	English	11.7±2.4m 12±2.7m	Sevoflurane	perineural	Dex(n=15g1ug/kg Control(n=15g1s): saline	the incidence of PONV, need for rescue analgesia
Peng 2015 <sup>15</sup>	China	English	3-24m	Sevoflurane, fentanyl, propofol, cisatracurium, remifentanil	intravenous	Dex(n=20) 0.8ug/kg/min (containuous intravenous infusion after induction) Control(n=20): saline	the incidence of EA, PONV, airway spasm
Boku	Japan	English	10-14m	Sevoflurane,	intravenous	$Dex(n=35) \frac{6}{2} 6ug/kg/h \qquad (10)$	the incidence of

Page 23 of 50

2

5 6

8

10

11

12

13

14 15

16

17

18 19

20

21

22 23

24

25

26 27

28

29

30

31 32

33

34

35 36

37

38 39

40

41 42 43

						6798	
						10mi <b>g</b> )	cough,
						Control( $n$ $\rightarrow 0$ ): saline	desaturation,
						, in the second	airway spasm
Xiao	China	Chinese	$1.22\pm0.22y$	Sevoflurane,	intravenous	Dex(n=18 2ug/kg (during	the incidence of
$2012^{20}$			$1.26\pm0.24y$	vecuronium,		induc <mark>g</mark> on)	EA, PONV,
			1.25±0.23y	propofol,		$+0.5 \frac{\dot{g}}{kg/h}$	desaturation
						(continuous	
						intravenous infusion	
						after Hatubation)	
						Control 1(g=18):2mg/kg	
						(during induction)	
						+0.5ngg/kg/h	
						(continuous	
						intravenous infusion	
						after intubation)	
						ketangine	
						Control 2(g=18):3ug/kg	
						(during induction) +	
						1ug/k	
						fentaryl	
Xi	China	Chinese	1-3y	Sevoflurane,	intravenous	Dex(n=15) 1ug/kg (30min	the incidence of
201221			Ž	midazolam		befor surgery finish	EA,
				propofol,		for10 min)	breath-holding,
				cisatracurium,		Control( $n = \frac{2}{5} = 15$ ): saline	desaturation,
				fentanyl		ਸੰਦ ਰ	airway spasm
						ed by co	
						ŏ	

						798	
Yun	China	Chinese	6m-3y	Sevoflurane,	intranasal	Dex(n=60)2ug/kg (30min)	the incidence of
$2016^{22}$				propofol,		befor	EA
				succinylcholine		Control(n₹60): saline	
Ju	China	Chinese	4m-3y	Propofol,	intravenous	Dex(n=40 0.5 ug/kg	the incidence of
$2013^{23}$				cisatracurium,		(10mg before surgery	EA, need for
				fentanyl		start <b>fo</b> r 10min)	rescue
				sevoflurane,		Control(n=₹40): saline	analgesia,
				remifentanil		oad	PONV,
						ed f	Desaturation
Jun	China	Chinese	1.71±0.61y	Sevoflurane,	intravenous	$Dex(n=11 \hat{\mathbf{g}}): 0.5 \text{ug/kg/h}$	the incidence of
$2018^{24}$			$1.74\pm0.62y$	propofol,		(20mm before surgery	EA,
				rocuronium,		finished)	hypotension,
				sufentanil		Control(n ₹ 10): saline	Bradycardia,
						ēn. <del>.</del>	postoperative
					1/0.	<mark>эщ</mark> .	bleeding

dexmedetDA dexamethasoneagitation; PONV: postoperative nausea and vomiting.

Table 2 Individual Randomized Controlled Trial Methodological Quality.

			<b>~</b>			oad	
Study (year)	Adequate	Allocation	Blinding of	Blinding of	Incomplete	Fre of selective	Free of other
	sequence	concealment	Participants	Outcome	outcome data	reperting	bias
	generation		and Personnel	Assessment	addressed	http	
				<i>L</i>		http://bi	
Mostafa2020 <sup>12</sup>	yes	?	yes	yes	yes	ye <u>s</u>	yes
El-Emam2019 <sup>13</sup>	yes	yes	No	yes	yes	No₽	yes
Obayah2010 <sup>14</sup>	?	yes	No	No	yes	ye. <mark>s</mark>	yes
Peng2015 <sup>15</sup>	yes	yes	No	No	No	Non ? on	yes
Boku2015 <sup>16</sup>	yes	?	yes	yes	yes	? on	yes
Surana2017 <sup>17</sup>	yes	yes	yes	yes	yes	ye <b>≩</b>	yes
Luo2017 <sup>18</sup>	yes	?	yes	yes	yes	yeş ye <u>ş</u> yeş	No
Mei2014 <sup>19</sup>	yes	?	No	No	yes	yes	yes
Xiao2012 <sup>20</sup>	No	?	No	No	yes	yes yes	yes
Xi2012 <sup>21</sup>	?	?	No	No	yes	No	yes
Yun2016 <sup>22</sup>	yes	?	yes	No	yes	Noga yeag yeag	yes
Ju2013 <sup>23</sup>	?	?	No	No	yes		yes
Jun2018 <sup>24</sup>	yes	?	No	No	yes	yesu Nog	yes

Yes=low risk of bias; No=high risk of bias; ?=unclear risk of bias.

 /bmjopen-2020-046798 on 16 August 2021. Downloaded from h

Table 3 Summary of findings for the main outcomes

Dexmedetomidine for	cleft lip ar	ıd palate repair
---------------------	--------------	------------------

Patient or population: patients with cleft lip and palate repair

**Settings:** surgery

Intervention: Dexmedetomidine

Outcomes	Illustrative compa	rative risks* (95% CI)	Relative effect	No of Participants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Control	Dexmedetomidine			n A	
Emergence agitation	Study population		RR 0.19			
	458 per 1000	87 per 1000	(0.10 to 0.36)		low <sup>1,2,3,4,5</sup>	
		(46 to 165)			24 b	
Respiratory adverse events	Study population		RR 0.49	794	⊕ ⊕ ⊕ ⊖ moderate <sup>1,6</sup>	
	103 per 1000	50 per 1000	(0.31 to 0.78)		ກ່ → moderate <sup>1,6</sup>	
		(32 to 80)			rote	
The need for postoperative rescue analgesics	Study population		RR 0.27	293		
					<del>5</del> < 0	

jopen.bmj.com/ on

pril 18, 2024 by guest.

Protected by copyright

					702
	592 per 1000	160 per 1000	(0.1 to 0.73)	(5 studies)	moderate <sup>1,2,6</sup>
		(59 to 432)			
Cardiovascular adverse events	Study population		RR 0.83	880	
	105 per 1000	87 per 1000	(0.52 to 1.31)	(3 studies)	moderate <sup>1</sup>
		(55 to 138)			<u> </u>
Postoperative Nausea and vomiting	Study population		RR 0.92	524	
	63 per 1000	58 per 1000	(0.47 to 1.80)	(8 studies)	low <sup>1</sup>
·		(30 to 113)			D

<sup>\*</sup>The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence in risk (and its 95% confidence in risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

<sup>&</sup>lt;sup>1</sup> Allocation concealment and/or blinding of outcome assessors unclear/inadequate in 50% or more of the included studies


 $<sup>^{2}</sup>$  Significant heterogeneity (I 2 > 50%) is partially explained by different administration method ,dose and comparators.

<sup>&</sup>lt;sup>3</sup> Use of several different scoring criterias to evaluate emergence agitation.


<sup>&</sup>lt;sup>4</sup> a dose response gradient was present

<sup>&</sup>lt;sup>5</sup> RR >5 or <0.2

<sup>&</sup>lt;sup>6</sup> RR >2 or <0.5




Flow diagram of the literature search strategy  $82x73mm (300 \times 300 DPI)$ 



Risk of bias of the included studies.

210x86mm (300 x 300 DPI)



Perioperative dexmedetomidine versus control groups for emergence agitation (EA). CI: confidence interval; RR: risk ratio.

205x114mm (300 x 300 DPI)

**#1 dexmedetomidine [MeSH Terms]** 

#2 "cleft palate"[All Fields] OR "lip palate"[All Fields] OR "cleft palate and lip"[All Fields]

#3 infant or children or pediatric patient [All Fields]

#4 randomized controlled trial [All Fields]

#5 #1 and #2 and #3 and #4

# Risk of bias

# Mostafa2020<sup>12</sup> (ClinicalTrials.gov ID: NCT03412474).

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated program of random numbers
Allocation concealment (selection bias)	unclear	Not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Neither the doctors (investigators) nor the patients' guardians or even the children themselves were aware of the group allocation and the drug received. One anesthesiologist not involved in the block implementation or the data collection, prepared all the study solutions.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	While a third, blinded to the previous protocol, was responsible only for data collection.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 80 patients
Other bias	Low risk	Groups well balanced

# El-Emam2019<sup>13</sup> Clinical Trials.gov (NCT03480607)

	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	computer-generated randomization numbers
Allocation concealment (selection bias)	Low risk	a closed-seal envelope
Blinding of participants and personnel (performance bias) All outcomes	High risk	The principal investigator prepared the drug and performed the block
Blinding of outcome assessment (detection bias) All outcomes	Low risk	the person observing and recording the parameters was blinded to the study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	High risk	The primary outcome was to compare both groups regarding time to first rescue analgesic, while the primary outcomes in the pre-registration site were postoperative FLACC scale and postoperative sedation score.
Other bias	Low risk	Groups well balanced
		en.bmj.com/site/about/guidelines.xhtml

### Obayah2010<sup>14</sup>

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomly allocated" , no details
Allocation concealment (selection bias)	Low risk	The randomization was achieved by the opening of a sealed envelope by the attending physician
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 30 patients
Other bias	Low risk	Groups well balanced

Peng2015<sup>15</sup> Chinese Clinical Trial Register (ChiCTR-TRC-13003865).

Bias	Authors'	Support for judgement
	judgement	, ,
Random sequence	Low risk	Randomly divided with a computer-
generation (selection	LOW HSK	generated sequence of numbers
bias)		generated sequence of numbers
Allocation concealment	Low risk	
(selection bias)	LOW TISK	a sealed envelop
Blinding of participants	High risk	Not mentioned
	riigii iisk	Thot mentioned
and personnel		
(performance bias)		
All outcomes		
Blinding of outcome	High risk	Not mentioned.
assessment (detection		
bias)		
All outcomes		
Incomplete outcome	High risk	The actual sample was 40 while the planned
data (attrition bias)		sample in the pre-registration site was 60.
All outcomes		
Selective reporting	High risk	The primary outcome was to compare both
(reporting bias)		groups regarding emergence agitation and
		time about recovery parameters while the
		primary outcomes in the pre-registration
		site were heart rate and blood pressure.
Other bias	Low risk	Groups well balanced

# **Boku2015**<sup>16</sup> (UMIN 000009869) http://upload.umin.ac.jp.

D:		
Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	A computer-generated
generation (selection		random number table
bias)		
Allocation concealment	Unclear risk	Not mentioned.
(selection bias)		
Blinding of participants	Low risk	The patient's parents and the attending
and personnel		anesthesiologist were blinded to the group
(performance bias)		allocation
All outcomes	4	
Blinding of outcome	Low risk	Data for each patient were
assessment (detection		obtained by
bias)		the blinded anesthesiologist.
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)		
All outcomes		
Selective reporting	Unclear risk	Do not get the protocol
(reporting bias)		4.0
Other bias	Low risk	Groups well balanced

## Surana2017<sup>17</sup>

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	a computer-generated randomized chart
generation (selection	LOW HISK	a computer-generated randomized chart
bias)		
Allocation concealment	Low risk	The random group
(selection bias)	LOW TISK	assignments were enclosed in a sealed
(Sciection bids)		opaque envelope
Blinding of participants	Low risk	the surgeons, the patients, and the
and personnel	LOW 113K	anesthesiologist in the post-anesthesia
(performance bias)		care unit (PACU) were all blinded
All outcomes		dare unit (17166) were all billided
Blinding of outcome	Low risk	Data was recorded by a blinded observer.
assessment (detection	LOW TISK	Butta was recorded by a billiaca observer.
bias)		
All outcomes		
Incomplete outcome	Low risk	No loss to follow-up
data (attrition bias)	2011 1100	The look to lone. Ap
All outcomes		>
Selective reporting	Low risk	The authors provided results for all
(reporting bias)		measurements for 60 patients
Other bias	Low risk	Groups well balanced
		<u> </u>

#### Luo2017<sup>18</sup>

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	a computer-generated table of random numbers
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All pharmacological agents used in the present study were prepared and administrated by the anesthesiologists who were blinded to the details of the study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Pediatric Anesthesia Emergence Delirium and CHIPPS scores were documented by a well-trained PACU nurse who was blinded to the study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	4 patients from group DS and 3 patients from group SF were excluded from the analysis
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 93 patients
Other bias	High risk	Groups well balanced. Not in intention-to-treat: Of the 100 patients admitted to the study, 7 were later excluded by the authors for the reasons listed in table II, leaving data from 93 patients for consideration

## Mei2014<sup>19</sup>

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	a table of random numbers, no detail
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 60 patients
Other bias	Low risk	Groups well balanced.

### Xiao2012<sup>20</sup>

	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	randomized according to the operation time sequence
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 54 patients
Other bias	Low risk	Groups well balanced.

#### Xi2012<sup>21</sup>

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random mentioned, no detail
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
Selective reporting (reporting bias)	High risk	Lack of complications, such as postoperative hoarseness, nausea and vomiting
Other bias	Low risk	Groups well balanced.

#### Yun2016<sup>22</sup>

	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	a table of random numbers, no detail
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	A blinded anesthesia nurse prepared and administrated drugs
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 120 patients
Other bias	Low risk	Groups well balanced.

#### $Ju2013^{23}$

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Mentioned random, no detail
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up.
Selective reporting (reporting bias)	Low risk	The authors provided results for all measurements for 80 patients
Other bias	Low risk	Groups well balanced.

#### Jun2018<sup>24</sup>

Random sequence generation (selection bias)  Allocation concealment (selection bias)  Blinding of participants and personnel (performance bias)  All outcomes  Blinding of outcome assessment (detection bias)  All outcomes  Incomplete outcome data (attrition bias)  All outcomes  Selective reporting (reporting bias)  Other bias  Low risk  Compute randomized  Alloutemes.  Not mentioned.  Not mentioned.  Not mentioned.  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.  Other bias  Compute randomized  Not mentioned.	Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)  Blinding of participants and personnel (performance bias) All outcomes  Blinding of outcome assessment (detection bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk  Not mentioned.  Not mentioned.  Not mentioned.  Not mentioned.  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	'	Low risk	Compute randomized
(selection bias)  Blinding of participants and personnel (performance bias) All outcomes  Blinding of outcome assessment (detection bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk  Not mentioned.  Not mentioned.  Not mentioned.  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	bias)		
and personnel (performance bias) All outcomes  Blinding of outcome assessment (detection bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.		Unclear risk	Not mentioned.
(performance bias) All outcomes  Blinding of outcome assessment (detection bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  Fig. 1. The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	Blinding of participants	High risk	Not mentioned.
Blinding of outcome assessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	and personnel		
Blinding of outcome assessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (reporting bias)  High risk Not mentioned.  No loss to follow-up.  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	(performance bias)		
assessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (reporting bias)  High risk The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	All outcomes	4	
bias) All outcomes  Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	Blinding of outcome	High risk	Not mentioned.
All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (reporting bias)  High risk to follow-up.  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	assessment (detection		
Incomplete outcome data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	bias)		
data (attrition bias) All outcomes  Selective reporting (reporting bias)  High risk both groups regarding extubation time and incision bleeding which were not mentioned in method.	All outcomes		
All outcomes  Selective reporting High risk  (reporting bias)  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	Incomplete outcome	Low risk	No loss to follow-up.
Selective reporting High risk  (reporting bias)  The secondary outcomes were to compare both groups regarding extubation time and incision bleeding which were not mentioned in method.	data (attrition bias)		
(reporting bias)  both groups regarding extubation time and incision bleeding which were not mentioned in method.	All outcomes		
incision bleeding which were not mentioned in method.	Selective reporting	High risk	The secondary outcomes were to compare
mentioned in method.	(reporting bias)		both groups regarding extubation time and
Other bias Low risk Groups well balanced.			
	Other bias	Low risk	Groups well balanced.

outcomes	study	Begg's Test
EA	7	0.086
PONV	8	0.060
Respiratory adverse events	8	0.230
Cardiovascular adverse events	2	_
The need for postoperative rescue analgesics	5	0.462

#### EA:

	Dexmedetomid	ine group	Control g	roup
study	events	Total	events	total
Ju2013	0	40	0	40
Luo2017	4	50	4	50
Mei2014	0	30	1	30
Obayah2010	4	15	3	15
Peng2015	1	20	2	20
Surana2017	0	30	0	30
Xiao2012	1	18	2	18

#### Begg's test

```
adj. Kendall's Score (P-Q) = -8

Std. Dev. of Score = 4.08

Number of Studies = 5

z = -1.96

Pr > |z| = 0.050

z = 1.71 (continuity corrected)

Pr > |z| = 0.086 (continuity corrected)
```

#### PONV

	Dexmedetomidine group		Contro	l group
study	events	Total	events	Total
Ju2013	0	40	0	40
Luo2017	4	50	4	50
Mei2014	0	30	1	30
Obayah2010	4	15	3	15
Peng2015	1	20	2	20
Surana2017	0	30	0	30
Xiao2012	1	18	2	18
El-Emam 2019	4	50	3	50

#### Begg's test

adj. Kendall's Score (P-Q) = 
$$-11$$
  
Std. Dev. of Score =  $5.32$   
Number of Studies =  $6$   
 $z = -2.07$   
 $Pr > |z| = 0.039$   
 $z = 1.88$  (continuity corrected)  
 $Pr > |z| = 0.060$  (continuity corrected)

#### Respiratory adverse events

	Dexmedetor	midine group	Contro	l group
study	events	Total	study	events
Boku2015	2	35	2	35
Ju2013	0	40	4	40
Luo2017	2	30	4	30
Mei2014	13	50	25	50
Peng2015	1	20	3	20
Surana2017	0	30	0	30
Xiao2012	0	18	2	36
Xi2012	1	30	5	30

#### Begg's test

adj. Kendall's Score 
$$(P-Q) = -9$$
  
Std. Dev. of Score = 6.66  
Number of Studies = 7  
 $z = -1.35$   
 $Pr > |z| = 0.176$   
 $z = 1.20$  (continuity corrected)  
 $Pr > |z| = 0.230$  (continuity corrected)

### The need for postoperative rescue analgesics

	Dexmedetomidine group		Control group	
study	events	Total	study	events
Mostafa 2020	0	15	15	15
Obayah2010	10	15	15	15
Luo2017	5	46	29	47
Surana2017	7	30	20	30
Ju2013	2	40	8	40

#### Begg's test

```
adj. Kendall's Score (P-Q) = -4

Std. Dev. of Score = 4.08

Number of Studies = 5

z = -0.98

Pr > |z| = 0.327

z = 0.73 (continuity corrected)

Pr > |z| = 0.462 (continuity corrected)
```



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE		1 6	1-2
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1-2
ABSTRACT		ust 2	3-4
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION		ad a	5
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS		3//bm	6-8
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study guthors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g.el²) for each metatanalysis pen.bmj.com/site/about/guidelines.xhtml	6-7

BMJ Open

136/bmjopen-2020-0



44

45 46

# PRISMA 2009 Checklist

ny assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective within studies).	Reported on page #
	7-8
methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, which were pre-specified.	
. Do	8-12,21-27
	8-9
	9,21-24
ata on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9,25
	9,10
esults of each meta-analysis done, including confidence intervals and measures of consistency.	10-12
esults of any assessment of risk of bias across studies (see Item 15).	9-10,26-27
Its of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
<del>5</del> 2	12-15
	12-13
	14
general interpretation of the results in the context of other evidence, and implications for future research.	14,15
Prot	15
	15
	there of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at ge, ideally with a flow diagram.  study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and ne citations.  lata on risk of bias of each study and, if available, any outcome level assessment (see item 12).  tcomes considered (benefits or harms), present, for each study: (a) simple summary data for each on group (b) effect estimates and confidence intervals, ideally with a forest plot.  esults of each meta-analysis done, including confidence intervals and measures of consistency.  esults of any assessment of risk of bias across studies (see Item 15).  alts of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  be the main findings including the strength of evidence for each main outcome; consider their relevance to be (e.g., healthcare providers, users, and policy makers).  consider their relevance to general interpretation of the results in the context of other evidence, and implications for funders for the interview.

41
42 From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.